Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. by Boland, Barry et al.
NRDD CLEARANCE TEXT AND BOXES RESUBMITTEDs 04 MAY 2018  1 
 
Promoting the clearance of neurotoxic proteins in 
neurodegenerative disorders of aging 
 
Barry Boland1*, Wai Haung Yu2*, Olga Corti3, Bertrand Mollereau4, Alexandre Henriques5, 
Erwan Bezard6, Greg M Pastores7, David C Rubinsztein8, Ralph A. Nixon9,10, Michael R. 
Duchen11, Giovanna R Mallucci12, Guido Kroemer13-19, Beth Levine20,21, Eeva-Liisa Eskelinen22, 
Fanny Mochel23, Michael Spedding24, Caroline Louis25, Olivier R Martin26, Mark J Millan25*# 
 
 
*Equal first authors 
 
 #Corresponding author:  
mark.millan@servier.com 
 
 
1Dept. of Pharmacology and Therapeutics, University College Cork, Ireland; 2Dept. of Pathology 
and Cell Biology, Taub Institute for Alzheimer’s Disease Research, Columbia University; 3ICM 
Institute for Brain and Spinal Cord, Paris, France; 4 Université de Lyon, ENSL, UCBL, CNRS, 
LBMC, Lyon, France; 5Department of Pharmacology, Neuro-Sys, Gardanne, France; 6CNRS, 
Institut des Maladies Neurodégénératives, Bordeaux, France; 7Department of Metabolic 
Diseases, Mater Misericordiae University Hospital, Dublin, Ireland, 8Department of Medical 
Genetics, Cambridge Institute for Medical Research, University of Cambridge and UK Dementia 
Research Institute, Cambridge Biomedical Campus, Cambridge, UK; 9Center for Dementia 
Research, Nathan Kline Institute, Orangeburg, New York 10962; 10Department of Psychiatry, 
New York University School of Medicine, New York, USA; 11UCL Consortium for Mitochondrial 
Research and Department of Cell and Developmental Biology, University College London, 
London, UK; 12Department of Clinical Neurosciences, University of Cambridge, UK; 13 Université 
Paris Descartes/Paris V, Sorbonne Paris Cité, Paris 75006, France;14Université Pierre et Marie 
Curie/Paris VI, Paris 75006, France; 15Equipe 11 labellisée Ligue contre le Cancer, Centre de 
Recherche des Cordeliers, Paris 75006, France; 16INSERM, U1138, Paris 75006, France; 
17Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, 
Villejuif 94805, France; 18Karolinska Institute, Department of Women’s and Children’s Health, 
Karolinska University Hospital, Stockholm 17176, Sweden; 19Pôle de Biologie, Hopitâl Européen 
George Pompidou (AP-HP), Paris 75015, France; 20Center for Autophagy Research, University 
of Texas Southwestern Medical Center, Dallas, Texas 75390, USA; 21Howard Hughes Medical 
Institute, Dallas, Texas, USA; 22Division of Biochemistry, University of Turku, Finland; 23INSERM 
U 1127, Brain and Spine Institute, Paris, France; 24Spedding Research Solutions SARL, le 
Vesinet, France; 25Centre for Therapeutic Innovation in Neuropsychiatry, IDR Servier, 78290 
Croissy sur Seine, France and 26Université d'Orléans & CNRS, Institut de Chimie Organique et 
Analytique (ICOA), Orléans, France. 
 
NRDD CLEARANCE TEXT AND BOXES RESUBMITTEDs 04 MAY 2018  2 
 
 
Abstract  
 
Neurodegenerative disorders of ageing (NDAs) like Alzheimer’s disease, Parkinson’s disease, 
frontotemporal dementia, Huntington’s disease and amyotrophic lateral sclerosis represent a 
major socio-economic challenge in view of their high prevalence yet poor treatment. They are 
often called proteinopathies in view of the presence of misfolded and aggregated proteins that 
lose their physiological roles and acquire neurotoxic properties. One reason underlying the 
accumulation and spread of oligomeric forms of neurotoxic proteins is insufficient clearance by 
the autophagic-lysosomal network. Several other clearance pathways are likewise compromised 
in NDAs: chaperone-mediated autophagy, the ubiquitin-proteasome system, extracellular 
clearance by proteases, and extrusion into the circulation via the blood-brain barrier and 
glymphatic system. The present article focuses on emerging mechanisms for enhancing 
neurotoxic protein clearance, a strategy that may curtail the onset and slow the progression of 
NDAs. 
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Neurodegenerative disorders of ageing, neurotoxic proteins and the importance of 
their clearance 
  Neurodegenerative disorders of ageing (NDAs) include Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), 
frontotemporal dementia (FTD) and related tauopathies. They are ultimately fatal, have no 
disease-modifying therapies and are associated with an increasing socioeconomic burden due to 
their rising incidence. These “proteinopathies” display complex and partly distinctive 
pathophysiological profiles, yet all share a cardinal feature: accumulation of aberrantly-
processed and misfolded proteins like amyloid--protein (A), tau, -synuclein, TAR DNA-
Protein 43 (TDP-43) and the polyglutamine protein, huntingtin (Htt). In NDAs, these proteins 
lose their physiological roles, aggregate and acquire novel neurotoxic functions1, with an 
impairment of elimination implicated in their their buildup and spread1-5. 
  As summarized in Figure 1, several endogenous mechanisms account for neurotoxic 
protein clearance. The glymphatic system and the blood-brain-barrier (BBB) extrude 
neurotoxic proteins from the extracellular space, interstitial fluid (ISF) and cerebrospinal fluid 
(CSF), where they may also be degraded by proteases or phagocytosed by microglia and 
astrocytes. Within neurons and other cell types, intracellular elimination is predominantly 
effected by the ubiquitin-proteasome system (UPS), chaperone-mediated autophagy (CMA) and 
the autophagic-lysosomal network (ALN) (Figure 2). Owing to its predilection for aggregated 
forms of neurotoxic proteins, as well as damaged organelles which likewise build up in NDAs, 
the ALN is an especially attractive target for disease-modification. However, it is unlikely that 
modulation of the ALN will prove to be a panacea1,4,5. Thus, we likewise discuss opportunities for 
harnessing non-ALN driven mechanisms of clearance for course-alteration in NDAs2,3. 
 
The autophagic-lysosomal network 
Crucial role in clearing aggregated proteins  
Autophagy is a phylogenetically-conserved, cytosolic process essential for cellular 
homeostasis. Three basic types are recognised (Figure 2)3,4. 
Macroautophagy (“autophagy”) involves sequestration of cytosolic material into de novo 
synthesized, double-membrane-bound autophagosomes that deliver their contents to 
lysosomes for digestion. Autophagic flux (Box 1) describes the process from formation of the 
autophagosome isolation membrane to cargo digestion in the lysosome (Figures 2 and 3). 
Autophagy is crucial for the intracellular clearance of burdensome proteins in all cell types, 
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including  neurons. Further, astrocytes and several subtypes of microglia play important roles in 
the phagocytosis and subsequent elimination of extracellular pools of neurotoxic proteins6-8. In 
addition to bulk clearance of cytoplasmic contents, dedicated autophagy receptors promote 
sequestration of specific misfolded and/or aggregated proteins, damaged organelles, 
aggresomes, stress granules, peroxisomes, endoplasmic reticulum (ER)/Golgi components, 
lipids, ribosomes, polysaccharides and nucleic acids4,9. LC3-II and adaptor/scaffold receptor 
proteins like optineurin and p62 recruit discrete classes of protein to autophagosomes10. Other 
scaffolds include “Nix”, “BNIP1” and Prohibitin-2 for dysfunctional mitochondria (Box 2)4,9-11. 
Ubiquitin and non-ubiquitin dependent autophagy occurs, with ubiquitination of tau and other 
neurotoxic proteins enhancing capture by autophagic receptors like p62. Post-translational 
modifications like acetylation (e.g., of Htt) may favour ALN degradation, but await further 
evaluation12.  
The other two modes of autophagy are microautophagy, where cytosolic material is 
directly engulfed by invaginations of lysosomes, and chaperone-mediated autophagy (CMA), 
further discussed below.  
 Autophagy can be constitutive or inducible, rapidly adapting to alterations in the internal 
and external environment of cells. Flexibility is important for mainting normal brain function and 
for ensuring a constant supply of recycled amino acids, sugars, lipids and other products of ALN-
mediated catabolism3,13. That autophagy serves an essential housekeeping role is demonstrated 
by genetic ablation of autophagy-related genes (Atg). For example, mice with neuron-specific 
Atg7 or Atg5 deletions develop early post-natal neurodegeneration14, while knockdown of Beclin 
1 (Atg6) exacerbates the vulnerability of hippocampal neurons to energy deprivation15. 
Moreover, post-mitotic neurons cannot dilute harmful proteins via mitosis, so they are uniquely 
vulnerable to impairment of clearance1,3,5,16-18. 
Maintaining efficient ALN flux requires coordination of a suite of modulatory proteins and 
phospholipids (Figure 3)3,10 Changes in their amount, stoichiometry and function are 
characteristic of NDAs1-3,5,10,18-20. 
 
Operation and regulation of the ALN  
Sensing, initiation and regulation of ALN induction  
 The heterotrimeric serine/threonine kinase, AMP-regulated Kinase (AMPK), and 
mammalian target of rapamycin complex (mTORC1) respectively trigger and repress 
autophagy and mitophagy (Figure 3, Box 2)3,10,20-23. Unc-51-like kinase (Ulk1) is primarily an 
autophagy-initiating protein3,10,19, and the same holds true for mTORC1-suppressed 
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Transcription Factor EB (TFEB), which orchestrates the synthesis of lysosomal and other 
proteins critical for maintaining ALN flux20-23. Since the Class III deacetylase, Sirtuin-1, requires 
nicotinamide adenine dinucleotide to sustain its activity, this positive regulator of autophagy 
may also be considered as a sensor24.  
Intrinsic sensors detect changes in intracellular levels of glucose, amino acids, fatty 
acids, AMP, inositol triphosphate (IP3), cytosolic Ca2+, reactive oxygen species and metabolic 
intermediates such as acetyl coenzyme A (Box 2)5,13,19,21,23,25. For example, decreased glucose 
availability and impaired mitochondrial respiration compromise ATP production, leading to 
elevated levels of AMP and ADP which allosterically activate the -subunit of AMPK21. Extrinsic 
sensing occurs via drug-targetable mechanisms at the plasma membrane. First, receptor 
tyrosine kinases converge onto mTOR1, AMPK or the Beclin 1-Vps 34 complex (Figure 3) to 
modulate autophagy following stimulation by growth factors10,26. Second, G-protein coupled 
receptors (GPCRs) and ion-channel coupled receptors control autophagy via signalling 
pathways that likewise modulate AMPK and mTORC127-29. GPCR-mediated generation of cAMP 
can negatively regulate autophagy via, for example, protein kinase A (PKA)-mediated 
phosphorylation of Atg proteins27,29,30. Third, specific classes of cytokine and cytokine receptor 
also modulate autophagy, although events in the brain remain poorly defined23.  
 AMPK exerts several mechanisms that trigger autophagy. Most importantly, 
phosphorylation-activation of of Ulk1/2 (Ser317 and Ser777) and phosphorylation-inhibition of 
mTORC121,31. Conversely, mTORC1 inhibits Ulk1/2 by Ser757 phosphorylation3,4,31. MTORC1 
also restrains autophagy by preventing nuclear translocation of TFEB20. Other transcription 
factors that positively regulate autophagy include Forkhead-Box O1 and O322. Conversely, 
repression is effected by STAT3 (Signal Transducer and Activator of Transcription 3) and, 
possibly, “ZKSCAN3,” although its role has been disputed22,32. Sirtuin-1 is activated by AMPK-
mediated increases in nicotinamide: it drives the ALN by inhibition of mTORC1, induction of 
Forkhead-O1/O3, and activation of key regulatory proteins like Atg5, Atg7 and LC3. These 
actions comprise part of a broad palette of Sirtuin-1 mediated neuroprotective effects in NDAs24. 
 
Autophagosome formation, cargo sequestration and delivery to lysosomes 
Activation of Ulk1 triggers autophagosome nucleation through phosphorylation-activation 
of Beclin 1 within the autophagy-specific Vps 34 kinase complex10 (Figure 3). LC3 and other 
family members like “GABARAP” covalently conjugate with phosphatidylethanolamine and assist 
in elongation of the isolation membrane and closure of autophagosomes1,3,10,33. They also serve 
as docking sites for autophagy receptors that selectively capture ALN substrates (Box 1)3.  
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Compared to glia, the complex structure of neurons complicates ALN degradation 
of neurotoxic proteins1,8,10,18. Autophagosomes formed in synaptic terminals and neurites 
must be retrogradely transported with the aid of microtubules and dynein-dynactin motor 
complexes to the perikarya where lysosomal fusion occurs10,16,34. Indeed, many 
autophagosomes fuse with late endolysomal compartments containing membrane-
localised Rab7 protein (a GTPase) and Lysosome-Associated Membrane Protein (LAMP)1 
before reaching the perikaryon. This implies that the ALN process is partly intiatiated in 
advance of fusion with mature lysosomes and full luminal acidification, a process 
completed upon arrival in the perikaryon (Figure 2)10,16,34,35.  
Autolysosome formation is facilitated by the retromer complex, itself retrogradely 
transported to cell bodies36,37. “SNARE” proteins and the “Homotypic Fusion and Vacuole-
Protein Sorting” complex bridge mature autophagosomes/amphisomes to lysosomes to initiate 
fusion4,19. Rab proteins and LAMP1/2 collectively aid in autophagosome maturation and 
lysosomal fusion, which is also dependent on membrane constituents like Phospholipase D1, 
phosphoinositols and other phospholipids like cholesterol10,19,38. 
 
Lysosomal digestion of cargo  
Autophagosomes fuse with lysosomes that provide the hydrolases required for cargo 
degradation3,4,9,39. Hydrolases are dependent on a low pH, and lysosomal acidification is 
promoted by vacuolar-type H+-ATPase complex (v-ATPase) which pumps protons into the 
lysosomal lumen. The electrogenic potential created by proton import is mediated by multiple ion 
channels that influence lysosomal pH40. Underpinning the importance of acidity, digestion can be 
halted by v-ATPase inhibitors like bafilomycin A41 and lysosmotropic basic amphiphiles like 
chloroquine which alkalinize the lysosomal lumen42. Further, a deficiency of lysosomal 
cathepsins (B, L and D etc) prevents protein degradation and leads to accumulation of 
undigested cargo16,17,39. Lysosomal dysfunction blocks flux across the entire ALN, as evidenced 
by lysosomal storage diseases (LSDs) like Niemann-Pick Type C which manifest with 
neuropathological phenotypes (Suppl Box 1)43.  
In addition to ALN function, the importance of maintaining lysosomal activity reflects a 
broader role in, for example, regulation of cytosolic Ca2+ and energy homeostasis44. 
 
Chaperone-Mediated Autophagy  
Like autophagy, CMA is important for amino acid recycling during periods of poor 
nutrient availability but, in contrast, it involves transfer of protein substrates for 
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degradation into the lysosomal lumen without enclosure by any membrane structure 
(Figure 2)45-47. With the help of heat shock protein90 (Hsp90) and other co-chaperones, 
heat shock cognate protein70 (Hsc70) recognises soluble, cytosolic proteins bearing a 
KFERQ or equivalent motif and guides them to the transmembrane LAMP2A receptor1-
5,10,47. The substrate complex binds to the cytosolic tail of LAMP2A leading to LAMP2A 
stabilization and oligomerization: following unfolding of the protein cargo, it is then 
translocated into the lysosomal lumen. This process is aided by a specific, low pH-
dependent lysosomal form of Hsc70 (Lysine-Hsc70), which promotes dissociation of the 
LAMP2A multimer so that the monomeric form is again available for substrate recognition 
and import. The level of LAMP2A determines the rate of CMA. In contrast to ALN, CMA is 
not devoted to the degradation of higher-order neurotoxic proteins and aggregates, but it 
is important for clearing oxidized proteins. Tau,-synuclein and TDP-43 are substrates 
for CMA degradation, as well as APP but not A42 itself3,45-47,48. Htt is not efficiently 
cleared by CMA, and the same appears to hold for its fragments, mutant and post-
translationaly modified forms, although the precise role of CMA in Htt elimination remains 
to be more fully defined2,45-47.  
 
The Ubiquitin-Proteasomal System  
The UPS mainly targets soluble and monomeric proteins rather than aggregates, 
using a process involving Hsp70 and the sequential actions of three classes of ubiquitin 
ligase (E1, E2, and E3). They effect the addition onto targeted proteins of ubiquitin 
residues, often as polyubiquitin chains, at single or multiple lysine sites (Figure 2)2,3,8,48,49. 
Ubiquitinated substrates are recognised by the 19S regulatory particle of the UPS 
complex. After binding to the Rpn subunits of the 19S ring, ubiquitin motifs are removed 
by three enzymes, Usp14, Uch37 and Rpn11. Rpn11 removes ubiquitination chains only 
after substrates are committed to destruction, whereas Ups14 and probably Uch37 act 
before commitment and hence can rescue substrates49. Following removal of ubiquitin 
moieties, proteins are unfolded by the Rpt1-6 subunits (ATPases) of the 19S component. 
The substrate then passes the -subunit gate of the 20S core particle to enter its central 
β-subunit which possesses peptidase activity (trypsin, chymotrypsin and caspase-like) 
and effects proteolysis.  
In addition to ubiquitinated substrates, the UPS can also handle oxidized proteins which 
may accumulated under conditions of cellular stress8,50. Further, as well as cytosolic proteins, 
the UPS degrades mitochondrial proteins that build up upon failure of mitochondrial import or 
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sorting51. It also operates in the nucleus. Interestingly, the UPS is important for elimination of tau 
and other neurotoxic proteins in post-synaptic dendritic compartments (a key site of spreading), 
where it plays a more general role favouring synaptic plasticity, dendritogenesis and memory 
formation49,52. Susceptibility of neurotoxic proteins to ubiquitination is modified by 
phosphorylation and other post-translational modifications3,8,49,51.  
 
Defective ALN, CMA and UPS mediated clearance of neurotoxic proteins 
NDA-related impairments  
 Neurons adopt multiple strategies to deal with potentially-dangerous proteins. With the aid of 
chaperones like Hsp70, anomalously-configured proteins may be refolded or, if clumped in 
aggregates, disassociated2,3,53. Neurotoxic proteins may also be sequestered in insoluble tangles 
(tau) or in microtubule-associated aggresomes2,4. This intracellular lock-up may, at least initially, 
be neuroprotective, but continuing accumulation eventually poses a threat to cells underscoring 
the importance of elimination2,4. While clearance systems are, at least initially, recruited in NDAs, 
they eventually become unable to cope with the additional neurotoxic burden (Table 1)1,5,9,18,54,55. 
The partly common and partly disease-specific patterns of ALN, CMA and UPS disruption in 
NDAs are superimposed upon a generalized, age-related decline in clearance both in neurons 
and in other cell types like microglia1,2,7,18,46,47,55,56. Insufficient neuronal ALN flux is frequently 
manifested by lysosomal accumulation of lipofuscin18. 
For optimisation of therapy in NDAs, accurate interpretation of the causes of impaired 
elimination is paramount. This is challenging since it may be a repercussion of upstream 
anomalies like protein overproduction, misfolding or an excessive cytosolic Unfolded Protein 
Response (UPR) (Suppl Box 2)57. Further, it is difficult to identify the exact nature of UPS, CMA 
and ALN dysfunction (Box 1). While inadequate ALN flux is a common problem for all NDAs, 
under certain conditions ALN overactivity may contribute to pathology and even autosis4 in ALS 
(Suppl Box 3). 
 The following paragraphs and Table 1 summarize the complex patterns of defective 
neurotoxic protein clearance seen in specific classes of NDAs. 
 
Alzheimer’s disease 
While induced in the early phase of AD1,3,47,58, ALN, UPS and CMA-mediated clearance 
eventually becomes overwhelmed and impaired. First, autophagosomes and autophagic 
vacuoles indicative of failed maturation, transport and/or fusion with lysosomes are abundant, 
particularly in dystrophic neurites. Their accumulation may be linked to impaired lysosomal 
NRDD CLEARANCE TEXT AND BOXES RESUBMITTEDs 04 MAY 2018  10 
elimination of cargo18. Second, while decreases in Beclin 1 levels in AD remain to be confirmed, 
Sirtuin-1 expression is diminished24. Third, apolipoprotein E4 allele (ApoE4), a major risk allele 
for sporadic AD, is associated with increased generation and accumulation of A4259,60. ApoE4 
slows lysosomal A42 clearance and, like A42 itself, destabilizes lysosomal membranes. In 
addition to decreased degradation, one consequence is leakage of asparaginyl 
endopeptidase into the cytosol where it generates toxic fragments of tau61. Moreover, 
ApoE4 impairs the elimination of A42 and tau by astrocytes and microglia, additionally 
compromised by decreased activity of Triggering Receptor Expressed on Myeloid cells 
(TREM)27,62. Fourth, genetic mutations and anomalies of presenilin-1, a dominant-negative 
gene linked to AD, are associated with reduced lysosomal v-ATPase-mediated acidification40,63, 
a compromised ALN and deficient mitophagy64. Presenilin-2, likewise an autosomal-dominant 
risk gene, is enriched in late endosomes/lysosomes where its dysfunction provokes 
lysosomal accumulation of insoluble A42 and possibly tau65 Fifth, mutations in Amyloid 
precursor protein (APP), similarly disrupt endosomal and lysosomal function, in part due to 
accumulation of the -secretase-generated, carboxyl-terminal and Acontaining fragment of 
APP called C9966. Sixth, A42 compromises the function of AMPK to impede initiation of the 
ALN67. Finally, A42 obstructs the UPS and CMA47,68. Both aggregates and mutant forms 
of tau likewise block the proteasome, and its efficacy for degrading hyperphosphorylated 
and oligomeric tau is reduced compared to the physiological form3,55,68. Finally, while 
physiological tau possesses KFERQ motifs and is degraded by CMA, aggregates, mutant 
forms and fragments interfere with CMA45,47.  
 
Parkinson’s disease 
By analogy to AD, disrupted proteostasis is a major feature of PD, with the efficiency of 
ALN, CMA, UPS and other modes of clearance compromised by multiple cellular anomalies. 
First, autosomal-recessive forms of early-onset PD are associated with mutations in 
Phosphatase and Tensin Homolog-induced Putative Kinase (PINK1) and E3 ubiquitin ligase 
Parkin: these mutations lead to deficits in the mitophagic removal of damaged mitochondria 
(Box 2)69,70. Second, Leucine-Rich Repeat Kinase-2 GTPase is the most commonly “mutated" 
protein in late-onset, familial PD. Its role is complex, but mutations lead to an impairment of the 
ALN due to reduced activation of Beclin 1: another repercussion may be altered processing of 
APP, providing an unexpected link to AD69,71-73. Third,-synuclein mutations, triplication or 
excess amplify the ALN burden, interfere with autophagosome formation and irreversibly disrupt 
the lysosomal membrane1,3,44,56.  Fourth, homozygous mutations of lysosomal -
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glucocerebrosidase provoke the LSD, Gaucher’s Disease, which is linked to decreased ALN 
flux, -synuclein accumulation and a five-fold increase in risk for PD (Suppl Box 1)43. 
Decreased -glucocerebrosidase activity also occurs in sporadic PD leading to the build-up of 
glucosides, lipid dyshomeostasis, poor clearance of -synuclein and impaired lysosomal 
activity43,74,75. Fifth, defects in several genes disrupt lysosomal acidification40. For example, 
disruption of the ATPase, ATP13A2 (PARK9), which is also depleted in sporadic PD, leads to 
lysosomal alkalisation and digestive failure76 together with accumulation of -synuclein and other 
ubiquinated proteins76-78. Sixth, aggregates and mutant forms of -synuclein disrupt the 
proteasome in dopaminergic neurons. Further, mutations in Parkin and several other 
genes are linked to reduced UPS activity2,56,69,79,80. Finally, oligomeric and mutant forms of 
-synuclein impair LAMP2A-mediated cargo transport for CMA, while levels of both 
LAMP2A and Hsc70 are reduced in PD brain45,47,55,80. In addition, CMA is disrupted by 
several genetic mutations occurring in PD, including Leucine-Rich Repeat Kinase-22,3,45-
47,55,69,80. CMA dysfunction in PD favours the accumulation of -synuclein and leads to 
inactivation of the dopaminergic neuron survival factor, “MEF2D”2,45,47,55. 
 
Frontotemporal dementia 
As FTD was initially associated with tau mutations, it was originally considered a 
“tauopathy”81,82. However, in light of common risk genes like p62 (Sequestome1) and “C9orf72” 
(Chromosome 9 Open Reading Frame-72), FTD is increasingly linked to ALS82,83. Genetic 
anomalies in FTD are closely related to a deficient ALN, and, like ALS, the disease is 
characterised by aggregates containing tau, TDP43, Fused-in-Sarcoma and other ubiquitinated 
proteins insufficiently cleared by the ALN82,84. Aggregates interfere with the UPS to create a 
vicious circle that further overloads the ALN1,18,55,56,68,84. Recently, it was found that poly-
glycine/alanine tracts linked to mutant forms of the C9orf72 gene form twisted ribbon 
aggregates that sequester and stall the activity of proteasomes85. MAPT (tau) is a 
distinctive risk gene for FTD vs ALS, and dissociation of tau from microtubules disrupts 
retrograde transport of autophagosomes to the lysosome81,82. In addition, lysosomal dysfunction 
and loss of acidification is caused by tau fragments and a deficit of progranulin40,82,83,86, while an 
interrelated deficiency of endosomal trafficking is linked to mutations in “CHMP 2B” (Charged 
Multivesicular Body Protein 2B) as well as C9orf7282,83.  
 
Amyotrophic lateral sclerosis  
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 ALS shares many causal genes with FTD, including p62, CHMP2B, “TBK1” (Tank-
Binding Kinase 1), optineurin and others associated with deficits in ALN and mitophagy. For 
example, mutations in optineurin and TBK1 interfere with cargo loading82,84,87. Mutations in 
C9orf72 (the most prevalent risk gene for familial ALS and FTD) are likewise linked to disruption 
of the ALN, including interference with dynactin-dynein coordinated transport of 
autophagosomes along axons of motor neurons to the perikarya82,88. They also lead to 
deregulation of Rab-GTPases and a failure of autophagosome elongation89. Paradoxically, 
however, certain anomalies of C9orf72 may stimulate the ALN and, under conditions of severe 
cellular stress, high ALN activity may be detrimental (Suppl Box 3)48,88,90. In any event, 
depending on their genetic profiles, ALS patients reveal aggregates of risk gene-encoded 
proteins like TDP-43, optineurin, Fused in Sarcoma and/or superoxide dismutase 
(SOD1)48,82,84,87,89. Aggregated SOD1 and TDP-43 disrupt CMA and the UPS - with the latter 
also impaired by mutations in the C9orf72 gene2,8,47,48,55,85,91. Thus, mirroring other classes of 
NDA, a failure to clear neurotoxic proteins is characteristic of ALS48,82,84. 
 
Huntington’s disease 
   In this autosomal-dominant, polyglutamine disorder, an increase in CAG-expansion 
repeats in the HTT gene encoding Htt protein magnifies its propensity to oligomerise2,3,55,80. 
Mutant Htt is cleared by autophagy but it compromises the ALN because of decreased poor 
cargo loading and impaired autophagosome formation and transport55,56,68,92. Further, ALN 
disruption in the striatum (a region strongly impacted in HD) involves altered activity of the 
striatal-specific Beclin 1 and Htt-interacting protein “Rhes”93,94. In addition, loss of physiological 
Htt and abnormal polyQ-Htt perturb neuronal cilia, important sites of cellular communication and 
signaling which reciprocally interact with autophagic mechanisms controlling their formation and 
growth92. CMA only poorly handles mutant and post-translationally modified forms of Htt, 
which interfere with its activity2,45,47,95. While LAMP2A and Hsc70 are upregulated in early 
HD to compensate for decreased ALN clearance, CMA eventually fails in parallel with 
neuronal loss47,96. The status of the UPS in HD is currently unclear, but it only poorly 
cleaves mutant forms of Htt (and other polyglutamine tracts), while animal models 
suggest that impairment in HD, which would further lead to reduced clearance of Htt97. 
 
Strategies for enhancing neurotoxic protein clearance by the ALN 
Ultimately, any strategy that improves protein quality control and reduces 
excessive generation, aberrant processing and/or abnormal folding of neurotoxic 
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proteins should moderate the ALN burden and facilitate clearance. For example, agents 
that promote folding of nascent proteins, prevent misfolding, refold aberrantly-configured 
proteins, dissociate aggregates, counter ER stress and/or blunt an excessive UPR might 
pre-empt the build-up of neurotoxic proteins (Suppl Box 2)1,2,54,56,57,84,98-100. However, the 
present review focuses on strategies for elimination of neurotoxic proteins (Table 2 and Figure 
4). It should be noted that the precise mechanisms of drug action are not invariably well-defined4 
and that certain agents exert multiple beneficial (or deleterious) actions. For example, methylene 
blue counters tau oligomerization as well as promoting autophagy (Suppl Table 1)101,102. In 
addition, several drugs like resveratrol interact at multiple nodes of the ALN. Indeed, future drugs 
designed to act in a multi-modal manner may prove to be the most effective for enhancing 
clearance in NDAs.  
The following paragraphs mainly evoke classical “small molecules”: innovative treatment 
modes for reinforcing clearance are outlined in Box 3.  
 
Modulators of sensing, initiation and regulation  
Direct and indirect activators of AMPK-induced autophagy 
Ligands inhibiting GPCRs coupled to the AC-cAMP-PKA axis are potential activators of 
AMPK27,29. Indeed, clonidine and rilmenidine, two Gi/o coupled 2-adrenoceptor agonists, 
stimulate autophagy and clear Htt in cellular103 and animal models of HD104, although their 
precise mechanisms of action await further elucidation21,103,104. Calpains, Ca2+-activated cysteine 
proteases, are elevated in ageing and proteolytically generate various neurotoxic peptides54,81. 
They stimulate the AC-cAMP-PKA axis to inhibit AMPK by activation of GS103. Genetic 
knockdown of calpain or overexpression of its endogenous inhibitor, calpastatin, increased 
autophagy and cleared aggregates in SK-N-SH cells overexpressing a mutant form of Htt103. 
Efficacy was also seen in mutant Drosophila and mouse models of HD54. Calpeptin, a cell 
permeable calpain inhibitor, can also reduce Htt proteinopathy via induction of autophagy103,105. 
Calpain inhibition by calpastatin or pharmacological agents also confers neuroprotective effects 
in other NDAs models, including enhanced clearance of tau, -synuclein and SOD154,106,107. 
The aminoimidazole derivative, “AICAR,” undergoes intracellular transformation to an 
AMP analog that triggers AMPK-mediated autophagy21,108. It conferred neuroprotection upon 
exposure of astrocytes to Aor oxidative stress109 and countered -synuclein toxicity in cultured 
rat neurons110. Another direct facilitator of AMPK, A769662, elicited autophagy and reduced the 
burden of Htt in a striatal cell line derived from knockin mice expressing a humanized form of 
mutant Htt (Exon 1 containing 7 polyglutamine repeats111). Selenium deficits have been linked to 
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AD, so it is interesting that selenomethionine boosted ALN flux from AMPK recruitment through 
autophagosome formation to lysosomal degradation in the 3xTgAD mouse model112.  
The “anti-ageing” drug, resveratrol, is thought to indirectly recruit AMPK via activation of 
Calmodulin-Kinase-Kinase- which, acting in synergy with Ca2, exerts its effects via Thr172 
phosphorylation113. This action, amongst others (below), is involved in its reduction of A levels 
in N2a cells and neurons114 and the elimination of A and Htt in animal models of AD and 
HD114,115. 
The anti-diabetic drug, metformin, a prototypical activator of AMPK, induced autophagy 
and increased longevity in mice116. Like AICAR, metformin abrogated -synuclein toxicity in 
primary cultures of cortical neurons, though the precise contribution of autophagy requires 
clarification110. Moreover, reductions in levels of hyperphosphorylated tau and A were seen in 
metformin-treated neurons117,118, while it blunted neuronal loss in a neurochemical-lesion model 
of PD in mice119. 
The di-glucose derivative, trehalose, inhibits the “SLC2A” family of glucose transporters 
to promote AMPK-induced autophagy and reduce neurotoxic protein load, though it also exerts 
other actions downstream in the ALN4,120. Trehalose promoted autophagy and reduced disease 
progression in a SOD1 mouse model of ALS120. It also proved effective in cellular models of PD, 
HD and AD,121,122 as well as in mouse models of HD, AD and tauopathies where it cleared 
aggregates, reduced neurodegeneration and ameliorated motor and cognitive performance123-125. 
Lithium ions inhibit inositol monophosphatase to deplete inositol phosphate-3. This 
mechanism may be involved in its promotion of autophagy and reduction in cellular levels of -
synuclein, SOD1, Htt and tau126, amelioration of motor function in a P301L mouse model of 
tauopathy127, and slowing of disease progression in SOD1 mice128. However, its precise 
mechanism of action awaits further elucidation126. 
Other drugs that act through AMPK activation include the anti-aggregant, methylene blue 
(Suppl Box 1), which elevated levels of Beclin 1, p62 and LC3, induced autophagy and 
suppressed tau in organotypic neuronal cultures and a mouse model of FTD101,102. In addition, 
calcitriol (the active metabolite of vitamin D3) elicited AMPK-dependent autophagy in a 
neurochemical lesion-induced model of PD129. 
 
 
Modulators of mTORC1 and its transcriptional control of the ALN  
One major strategy for promoting autophagy is relief of repression by mTORC1. This 
kinase is classically inactivated by rapamycin that binds to the modulatory protein, “FKBP12” 
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(12-kDa FK506-binding protein). Enhancing autophagy with rapamycin reduced levels of -syn, 
Fused-in-Sarcoma and Htt130-132. It also diminished polyglutamine aggregates and countered 
motor impairment in a Drosophila model of HD133. In addition, rapamycin abrogated pathology in 
murine models of AD and FTD, as well as countering neuronal loss in MPTP-treated mice134-136. 
Likewise, temsirolimus reduced the accumulation of phosphorylated tau in SH-SY5Y cells and 
P301S tauopathy mice137. It also removed cellular aggregates of mutant Htt and improved motor 
performance in a mouse model of HD, reduced -synuclein aggregation and afforded 
neuroprotection in a lesion-based model of PD, and depleted mutant Ataxin-3 in a mouse model 
of supraspinal cerebellar ataxia-3133,138,139. Interestingly, several “small molecule enhancers of 
rapamycin” promoted autophagy and eliminated Htt in cellular and Drosophila models, but the 
precise role of mTORC1 in their actions remains to be clarified140. 
The naturally-occuring compound, curcumin, induced macroautophagy and 
neuroprotected rotenone-treated dopaminergic neurons141 as well as accelerating elimination of 
mutant A53T--synuclein by repression of mTORC1 in a cellular model of early-onset PD, 
although it also exerts other actions such as modulation of protein acetylation and 
aggregation142,143. Pro-autophagic effects of curcumin are reflected in improved function, as well 
as reduced levels of -synuclein aggregates144 and A/tau oligomers in cellular and animal 
models of PD and AD145,146.  
Inasmuch as phosphorylation by mTORC1 blocks translocation of TFEB from lysosomes 
to nuclei, mTORC1 inhibitors should promote the coordinated synthesis of proteins driving the 
ALN20,22,147. Indeed, TFEB over-expression reduced amyloid plaques in a APP/PS1 mouse 
model148. Moreover, the flavonol, fisetin, stimulated autophagic degradation of phosphorylated 
tau in cortical neurons via mTORC1-dependent activation of TFEB and the cytoprotective 
transcription factor, Nuclear factor Erythroid-2-Related factor 2 (Nrf2)149. Fisetin also reduced 
Aaccumulation in an APP/PS1 mice model of AD150. Thus, mTORC1 - and, possibly, AMPK via 
poorly-characterised cascades21 - offer channels into TFEB. It remains, nonetheless, a 
challenging target for induction22,151.  
”C-Abl” tyrosine kinase is a proto-oncogene that negatively regulates autophagy, partly 
acting upstream of the Akt-mTORC1 axis. It is over-activated in AD and tauopathies like FTD152. 
Inactivation of c-Abl with brain-penetrant nilotinib conferred neuroprotective autophagy in mouse 
models of PD153. It also reduced aggregates in cell and mouse models expressing TDP-43 
protein154. Nilotinib recently underwent a Phase I safety study for treatment of PD155. 
 
Modulators of Sirtuin-1 and inhibitors of acetyl transferases 
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Activity of the deacetylase Sirtuin-1 declines with age, partially due to limited availability 
of its co-factor, nicotinamide24,56,156. Therefore, it is interesting that nicotinamide and its 
analogues promoted autophagic removal of damaged mitochondria in fibroblasts157 and reduced 
A toxicity in rat cortical neurons158. They also improved mitochondrial energy generation and, 
partly as a consequence, reduced plaques in Aβ-expressing neuronal cells and AD mice, while 
improving cognitive function58. Nicotinamide analogues similarly slowed cognitive decline and 
neuropathology in a 3xTgAD mouse model of AD159.  
Resveratrol can stimulate Sirtuin-1 via AMPK (see above), and it also possesses an 
AMPK-independent mode of Sirtuin-1 recruitment that participates in blunting of the neurotoxicity 
of Aβ25-35 fragments in PC12 cells160. This possibly involves a role for the DNA-repair protein, 
poly(ADP-ribose)polymerase-1 (“PARP”). It’s pharmacological inhibition elevates levels of 
the substrate, nicotinamide, with an enhancement of mitochondrial energy generation 
contributing to neuroprotective properties in an animal model of AD160,161. 
Cilostazol (a phosphodiesterase-3 inhibitor) clears Aβ42 from neuronal cell lines by 
promoting autophagy, upregulating Beclin 1, Atg5 and LC3, down-regulating mTORC1, and 
inducing lysosomal cathepsin B: these actions of cilostazol involve activation of Sirtuin-1 as well 
as upstream Tyr-172 phosphorylation of AMPK108,162,163. Cilostazol improved cognition and 
reduced levels of A42 and hyperphosphorylated taufollowing intracerebroventricular injection of 
A(25-35) into mice162,163.  
Protein deacetylation, as effected by inducers of Sirtuin-1, is of broader relevance to the 
ALN as reflected in activation of Atg gene transcription20,24,164. Further, acetyl transferases like 
p300 are druggable20,165 and their inhibition (by garnicol) protected against autophagic deficits in 
a rodent model of PD166. Another p300 inhibitor, spermidine, has attracted attention by virtue of 
its autophagy-related increase in longevity164,167. Spermidine inhibited the acetylation of Atg 
proteins 7, 11 and 15 as well as that of histone 3, while inducing Beclin 1 via blockade of its 
cleavage through caspase-3168. Spermidine also decreased disease progression in a mouse 
model of FTD169 and reduced -synuclein toxicity in C. elegans170. Depletion of acetyl 
coenzyme-A would be worth exploring in models of NDAs171. Underpinning interest in inhibitors 
of acetyl transferase, p300 expression is increased in AD brain and involved in the aberrant 
acetylation of tau165,167,172,173. 
 
Inducers of autophagosome formation 
As outlined in Box 3, the cell-permeable peptide, Tat-Beclin 1, acts at the Beclin 1/Vsp 
34 complex to increase autophagy and promote the clearance of Htt aggregates in cell lines174. 
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In addition, the plant-derived alkaloid, isorhynchophylline, upregulated Beclin 1 independently of 
mTORC1 and promoted autophagic clearance of -synuclein, although its precise mechanism of 
action remains to be clarified175. Beclin 1 bears a “BH3” element on its N-terminus that is subject 
to inhibition by the anti-apoptotic protein, B-cell lymphoma (Bcl)-219,165,176. Disruption of this Bc-
l2/Beclin 1 complex is an alternative approach for promoting autophagy, as achieved in mouse 
fibroblasts by the BH3 mimetic, ABT-737177. A knockin, gain-of-function Beclin 1 mutant with 
reduced repression by Bcl-2 also increased autophagy, promoted A sequestration and 
improved cognition in a 5XFAD mouse model of AD: this pattern of effects was reproduced with 
ML246, a novel autophagy potentiator, with an uncertain mode of action178. Other potential 
approaches to Beclin 1 activation include inhibitors of (tau-phosphorylating) cyclin-dependent 
kinase-5179.  
The multi-modal agent, resveratrol, induced the expression of Atg4 and promoted 
autophagosome formation. This led to accelerated degradation of polyQ-Htt aggregates and 
protected SH-SY5Y cells from toxicity180. An unusual approach to augmenting autophagosome 
formation is represented by brain-penetrant “Autophagy Enhancer-99” (AUTEN-99) which blocks 
“Jumpy”, a phosphatase that inhibits the phosphotidyl-inositol-3-kinase-mediated generation of 
the autophagosome membrane (Figure 3). Auten-99 augmented autophagic flux in isolated 
neurons, increased markers of autophagy in mouse brain and slowed neurodegeneration in 
Drosophila models of PD and HD181.  
 
Promoters of autophagosome transport and lysosomal fusion  
Disruption of cytoskeletal networks and loss of microtubule function in NDAs 
compromises the transport of autophagosomes, late endosomes, amphisomes and 
retromers to perikaryal lysosomes, and hence impedes degradation of neurotoxic 
proteins34-36. Accumulation of autophagosomes and lysosomes in axonal swellings is 
associated with local APP processing into Aas well as plaque formation16,34. The 
microtubule stabilizers, paclitaxel and epothilone A, countered A-induced cytoskeletal 
disruption - and moderated excessive UPR - in neurons182. Further, epothilone D countered 
microtubule disruption and cognitive deficits in aged P301S/P19 AD mice183. However, it is 
unclear to what extent these agents promote ALN in the perikaryon, and a risk of cytoskeletal 
over-rigidity should not be neglected. Thus, mechanisms that promote microtubule/actin 
dynamics and cytoskeletal shuttling of autophagosomes/endosomes to lysosomes present 
alternative strategies for evaluation184. 
NRDD CLEARANCE TEXT AND BOXES RESUBMITTEDs 04 MAY 2018  18 
Several other, potentially-targettable mechanisms might also aid autophagosome delivery 
to (and fusion with) lysosomes185. These include Rab and Rab-effector proteins which facilitate 
the assembly of Synataxin17-SNARE complexes critical for fusion186.. Interestingly, genetic or 
pharmacological activation of Rab5 countered neurodegeneration in mouse C9orf72 
models of ALS and FTD187. There is also growing interest in the stabilization of retromers for 
promoting fusion. This appears feasible based on modulation of their role in diverting APP out of 
endosomes and hence curtailing its cleavage into A37,188. Finally, inducers of histone 
deacetylase-6, broadly implicated in cytosolic transport and the fusion of autophagosomes, 
might be an option3.  
 
Facilitators of lysosomal digestion  
Maintaining optimal intraluminal acidity is critical for activating lysosomal hydrolases and 
digesting cargo. There are several ways that a loss of lysosomal acidity in NDAs might be 
countered. First, lysosomal acidification could be favoured by stabilised cAMP analogues: in 
human fibroblasts bearing a Presenilin-1 mutation, cAMP acidified lysosomes and augmented 
the availability of cathepsins189. Second, the TFEB inducer, 2-hydroxypropyl-β-cyclodextrin 
promoted the acidity of lysosomes in neurons190. Third, acidic nanoparticles like polylactic acid 
and poly(lactide)co-glycolide increase acidification (Box 3). Fourth, activation of the lysosomal 
Ca2+ channel, “transient receptor potential mucolipin-1,” with a synthetic agonist (ML-SA1) 
increased intralysosomal Ca2+ and lowered pH191,192. Other approaches include the 
enhancement of v-ATPase activity, and countering deficiencies in progranulin activity40,63,86,193-195. 
Dysfunction of PARK9 (ATP13a2) leads to an imbalance in the handling of zinc, a 
disruption of lysosomal activity and accumulation of -synuclein77. Clioquinol, which acts as a 
metal-chelator, reverses these deficits and may reinforce lysosomal function (and acidification) in 
NDAs where the regulation of zinc and other metals is abnormal77,196. Indeed, clioquinol 
countered disruption of autophagy by chloroquine in retinal cells, reduced Aaccumulation in 
CHO cells expressing APP and mutant Presenilin-1, and diminished amyloid-misfolding and 
aggregation in Tg2576 AD mice196,197. Cystatin B and C are endogenous antagonists of the 
cysteine-active site on lysosomal cathepsins and their genetic down-regulation ameliorated 
deficits in lysosomal proteolysis, synaptic plasticity and amyloid clearance in TgCNRD8 AD 
mice198. Pharmacological blockers of cystatins are currently being sought. In addition, 
upregulation of retromer complex might stimulate provision of hydrolases to the lysosome37,188. 
Lysosomal enzyme replacement is a staple treatment for primary LSDs: for example, -
glucocerebrosidase supplementation for Type I (non-neuropathic) Gaucher’s Disease (Suppl 
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Box 1)43. Due to BBB impermeability, enzyme supplementation does not appear promising in 
PD. However, inhibition of substrate (glucosylceramide) synthesis by brain-penetrant GZ/667161 
and GZ/SAR402671 reversed synucleinopathy in A53T-SNCA mice199. Another 
glycosphingolipid synthesis blocker, miglustat,43 showed activity in cellular and in vivo models of 
PD75, although its ability to downregulate target sphingolipids in the brain is limited.  
One might also act upstream to promote lysosomal function by accelerating the import of 
functional enzymes. -glucocerebrosidase again provides a good example. Ambroxol acts as a 
molecular chaperone to promote folding of -glucocerebrosidase and aid its transit from the ER 
to lysosomes43. It increased expression of -glucocerebrosidase, normalised autophagy and 
accelerated degradation of -synuclein in a stem-cell model of dopaminergic neurons derived 
from PD patients bearing mutations for -glucocerebrosidase200. Ambroxol, which also 
decreased ER stress in Drosophila201, reduced -synuclein levels in overexpressing, transgenic 
mice202. It is being evaluated for use in idiopathic PD (Suppl Table 1). A downside of ambroxol is 
that it occludes the catalytic site of - glucocerebrosidase, but novel agents like NCGC607 avoid 
this untoward effect203. Intriguingly, while enhancement of -glucocerebrosidase conferred 
therapeutic benefit in animal models of PD, its inhibition by conduritol--epoxide was beneficial 
in a mouse model ALS, underpinning the apparently distinctive nature of ALS as regards ALN 
function and energy balance (Suppl Box 3)90.  
Finally, a more global approach for harnessing lysosomal activity would be the induction 
of TFEB20,22. Harnessing TFEB by 2-hydroxypropyl-β-cyclodextrin promoted clearance of 
proteolipid aggregates and -synuclein in a cellular model of PD195,204. It also augmented the 
elimination of A in a Tg19959/CRND8 mouse model of AD173. The protein kinase C activator, 
“HEP14”, stimulated nuclear translocation of TFEB to boost lysosomal gene transcription and 
reduced A plaques in APP/PS1 AD mouse brains151. Modulation of DNA methylation and post-
translational histone marking offer further opportunities for transcriptional control of lysosomal 
activity, while miRNAs could intervene at the level of translation (Box 3)20,165. 
 
 
Clinical studies of agents that modulate the ALN 
  Certain of the above-discussed agents have been clinically evaluated, alone or in 
association, in NDAs (Suppl Table 1). For example, metformin for cognitive function and 
energetic status in AD; resveratrol for functional decline and A load in AD; rilmenidine for motor 
performance in HD; and ambroxol for -glucocerebrosidase activity and motor function in PD. To 
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date, despite some positive observations, unequivocal proof for symptomatic 
improvement and/or course-altering effects has not been provided for any drug (Suppl 
Table 1). Nonetheless, long-term effects remain under study, no medication that 
specifically and exclusively induces the ALN has as yet been therapeutically 
characterized, and proof of target engagement in clinical trials remains challenging. 
Hence, it is premature to draw conclusions as regards therapeutic efficacy.  
  In fact, the anti-oxidant, edavarone, which decreased autophagy in ischaemic brain and 
macrophages205, was recently authorized for use in a subset of ALS patients (Suppl Box 3)206. 
This appears paradoxical, but fits with the suggestion that high ALN flux is detrimental under 
conditions of severe cellular stress in ALS90. Whether decreased ALN flux is genuinely 
implicated in its clinical actions remains to be confirmed(Suppl Box 3)3,206. 
 
Caloric restriction and exercise mimetics for promoting ALN clearance   
Anti-ageing and lifespan-extending benefits of “caloric restriction mimetics” expressed 
across a range of multicellular organisms are related, at least in part, to the induction of AMPK 
and Sirtuin-1 leading to promotion of autophagy21,24,164,207. These mimetics are generally safe yet 
encompass drugs that reduce ATP availability by interfering with cerebral/neuronal glucose 
uptake. This may pose problems since compromised neuronal energy is itself a risk factor for 
NDAs like AD and PD25,164. Nonetheless, efforts to find well-tolerated, autophagy-inducing 
mimetics are continuing164 and clinical trials should prove instructive25,164. Further, there is 
increasing interest in pharmacological exercise mimics that exert putative neuroprotective 
properties via the modulation of AMPK, mTORC1, beclin 1 and other regulators of the ALN21,207.  
 
Strategies for enhancing neurotoxic protein clearance by the UPS and CMA  
Opportunities for pharmacological manipulation of the UPS and CMA are less well-
established than those for the ALN, but there are encouraging routes of progress2,45-47,55,56,68. 
Furthermore, the UPS inhibitor bortezmib is approved as a first-in-class treatment for multiple 
myeloma, indicating that clinical application of UPS modulators is possible3.  
 
Facilitation of chaperones acting on client proteins 
One approach for reinforcing the UPS focuses on agents that target chaperones involved 
in the handling and recognition of neurotoxic proteins2,68,208. Of particular interest is Hsp70 which 
interacts with the E3 ubiquitin ligase “CHIP” to aid ubiquitination of proteins destined for 
proteasomal destruction208. Hsp70 binds to heat shock factor 1 (HSF1) and, under conditions of 
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neurotoxic protein stress, their dissociation leads to mutual activation, with HSF1 driving 
transcriptional generation of Hsp70 and other chaperones that facilitate proteostasis208,209. 
Hsp70 also exerts a more general role in the refolding and disassociation of aggregated 
proteins2,3.  
One promising agent is the hydroxylamine derivative, arimoclomol, which increases the 
activity of Hsp70 by augmenting transcriptional activity of HSF1210. Arimoclomol rescued cultured 
motoneurons from oxidative stress and from the pro-apoptotic actions of staurosporine211. It also 
mediated the removal of mutant SOD1 aggregates and improved motor function in a mouse 
model of ALS212. Supporting interest in arimocomol, it mimicked recombinant Hsp70 in reversing 
lysosomal pathology in fibroblasts from patients with LSDs (Suppl Box 3). In an alternative 
approach, the rhodocyanine derivative, YM-1, allosterically promoted the activity of Hsp70 to 
enhance degradation of polyglutamine (polyQ) proteins: these findings suggest potential utility in 
HD213. Further, Hsp70 has been co-administered with inhibitors (IU1 and its more potent 
derivative, IU1-47) of the deubiquitinating enzyme, USP14, to enhance proteasomal degradation 
of tau214-216. USP14 inhibitors act by preventing deubiquitination rescue of tau and other UPS 
substrates like TDP43 and Ataxin-3. They may also effect allosteric changes in proteasomal 
subunits217. Interestingly, USP14 inhibitors promote the ubiquitination activation of Beclin 1 to 
recruit the ALN216  
Hsp90 counters the effects of Hsp70 by forming a complex with it to impede substrate 
ubiquitination: it likewise exerts a suppressive influence on HSF1210,218. Amongst compounds 
that inhibit Hsp90, geldanamycin promoted elimination of both hyperphosphorylated tau and 
oligomeric -synuclein in cell lines219,220. Moreover, geldanamycin reduced Lewy-like bodies221 
and Htt aggregates in Drosophila neurites222 and reduced tau in AD mice219. The less cytotoxic 
analogue of geldanamycin, 17-AAG, has improved brain penetrance. It decreased A levels,223  
improved memory224 and lowered tau in transgenic AD mice224. 17-AAG also reduced - 
synuclein oligomers in H4 cells220. Another Hsp90 inhibitor, HSP990, has shown promise in  
lowering Htt aggregates and improving motor performance in two mouse models of HD225   
 
Modulation of the phosphorylation status of the proteasome 
Numerous classes of kinase phosphorylate the proteasome68,226,227. Phosphodiesterase 
inhibitors protect cAMP from degradation to recruit protein kinase A and boost UPS activity. 
Accordingly, rolipram protected rat cortical neurons from A-induced synaptic disruption228. 
Further, in a transgenic tau mouse model of FTD where 26S proteasomal activity was impaired, 
rolipram attenuated markers of tauopathy, improved memory and protected synaptic integrity by 
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strengthening protein kinase A-mediated phosphorylation of the Rpn6 component of the 26S 
proteasomal subunit229,230. Rpn6 activation may also be involved in the anti-ageing effects of 
caloric restriction56,164. Interestingly, resveratrol inhibits phosphodiesterase-4, suggesting that 
proteasomal recruitment may be yet another component of its global impact on neurotoxic 
protein clearance113. One concern with phosphodiesterase inhibitors/protein kinase A inducers is 
their huge range of targets (including AMPK), but it may be possible to target proteasome-
specific isoforms. Further, acting upstream of cAMP is an alternative strategy. Chronic 
administration of CGS21680, a selective agonist of AC-coupled adenosine-2A receptors, 
restored proteasomal activity in cellular and murine models for HD via protein kinase A-
mediated Ser-120 phosphorylation of the Rtp6 component of the 19S subunit231.  
Another kinase that activates the proteasome (Rpt6 subunit) - and directs it to dendritic 
spines - is calmodulin-dependent kinase II227. It’s recruitment may account for proteasomal 
activation by the GABAA receptor antagonist, bicuculline52,232. Protein kinase G similarly 
activates the proteasome, and inhibition of cGMP breakdown by sildenafil reduced neurotoxic 
protein aggregation in cardiomyocytes, encouraging studies in NDAs68,226,227. P38 mitogen-
activated protein kinase indirectly influences the phosphorylation status of the proteasome, likely 
via cAMP signalling3,68,226,227. P38 depletion, or its blockade by PD169316, accelerated the 
degradation of ubiquinated proteins, promoted -synuclein clearance and improved cell 
survival233.  
Phosphorylation is a dynamic process, and small molecule inhibitors of the 
nuclear proteasome phosphatase, “UBLCP1” suggest that calcineurin and other 
phosphatases represent hitherto-unexploited targets for enhancing UPS-driven clearance 
of neurotoxic proteins227. 
 
Selective elimination of specific classes of neurotoxic protein 
An important question is whether the UPS can specifically clear neurotoxic proteins while 
safeguarding those that function normally. Several strategies are under exploration. First, 
cereblon is the substrate receptor for the E3 Ubiquitin ligase, Cullin Ring Ligase 4. It is 
specifically recognised by the immunomodulatory drug, pomalidomide, the binding of which 
changes ligase specificity to encourage degradation of discrete classes of protein234,235. Second, 
PROteolysis TArgeting ChimeraS (“PROTACS”) and related multi-functional compounds 
simultaneously bind a E3 ubiquitin ligase and a defined neurotoxic protein like tau to enhance 
polyubiquitination and UPS-driven removal (Box 3)234,236. Certain agents amplify PROTAC-
mediated breakdown of -synuclein233, while other classes of bifunctional ligand bind a target 
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protein plus Hsp70 to direct UPS degradation235. Third, target proteins can be bound by agents 
bearing bulky, hydrophobic adamantyl tags which provoke conformational instability and 
encourage proteasomal elimination234. Fourth, the cytosolic antibody receptor, “Tripartite Motif 
Protein 21” binds to protein-coupled antibodies, then recruits the UPS for  substrate degradation. 
This has been demonstrated for tau and could be adapted for degradation of other classes of 
neurotoxic protein237. Finally, “cellular inhibitor of apoptosis protein” specifically binds mutant 
SOD1 and drives it to proteasomal degradation. This provides another potential path to discrete 
elimination of unwanted proteins in NDAs238. 
 
Control of transcription factors generating UPS components 
The transcription factors, Nrf1 and Nrf2, are both substrates of proteasomal 
degradation, as well as inducers of proteasomal synthesis, and the latter has been 
specifically linked to NDAs239,240.  Further, Nrf2 is a master regulator of the anti-oxidant 
response and drives synthesis of lysosomal and anti-inflammatory proteins in addition to 
26S proteasome components149. Translocation of Nrf2 to the nucleus is promoted by 
triterpenoid derivatives that counter the ageing-related diminution of UPS activity241. In addition, 
sulforaphane elevates proteasome levels in vivo by inducing Nrf2, protects neurons against 
oxidative stress, and has been proposed for the treatment of HD242. Several other agents 
promote the proteolytic competence of proteasomes and facilitate clearance of A and/or tau in 
cellular models, including betulinic acid. Enhanced transcription has been implicated in their 
actions, but this remains to be clarified242. Finally, mirroring its inhibitory influence on the 
ALN, mTORC1 suppresses the UPS by impeding the formation and assembly of 
proteasomal subunits. Correspondingly, pharmacological blockade of mTOR may 
promote UPS degradation as well as ALN elimination of neurotoxic proteins243.  
 
Enhancement of CMA-mediated clearance 
Certain mechanisms outlined above for the UPS, like increasing chaperone-driven 
delivery of client proteins to degradative machinery,  are also relevant to the CMA47,48,95. In fact, 
specific induction of CMA has received little attention, possibly since the rate-limiting element 
LAMP2A has, to date, proven intractable for small molecule chemistry. Nonetheless, over-
expression of LAMP2A accelerated CMA clearance of -synuclein and afforded protection 
of dopaminergic neurons45, and several routes to potential pharmacological exploitation 
may be mentioned. First, cathepsin A cleaves LAMP2A, resulting in its lysosomal 
degradation, so selective inhibitors of cathepsin A should reinforce CMA39,47,48. Second, 
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LAMP2A is stored in cholesterol-rich membrane regions: hence, cholesterol depletion 
might enhance transfer to regions where it is functionally active46. Third, the dynamics of 
the LAMPA2A-client protein translocation complex are (oppositely) controlled by 
mTORC2 and the phosphatase “PHLPP1”, offering potential targets for augmenting 
CMA244. Fourth, CMA is under the negative control of retinoic acid receptorand their blockade 
by synthetic, all-trans retinoic acid derivatives resulted in upregulation of CMA, including the 
activity of LAMP2A245. Mouse fibroblasts treated with these agents showed improved resistance 
to combined over-expression of -synuclein and oxidative stress245.  
  
Importance of early intervention  
There are, then, emerging opportunities for intensifying the elimination of neurotoxic 
proteins by the UPS and CMA47,68,227. However, it is important that they are homeostatically 
regulated since - mirroring the ALN - excess activity is potentially dangerous241. As the UPS and 
CMA are disrupted by neurotoxic proteins like A42 and tau, their early and preventative 
reinforcement may be critical. UPS potentiation might be particularly efficacious when enacted in 
dendritic sites of neurotoxic protein spreading to counteract NDA-related deficits in synaptic 
plasticity and learning1,3,5,8,47,52,68,227. 
 
Interplay between the ALN, CMA and the UPS: therapeutic relevance 
As pointed out above, there is evidence of coordinated regulation of the ALN and 
UPS via mTORC11,3,5,243. Furthermore, studies of a mutant tau allele that increases the risk for 
FTD and AD showed that upregulating the ALN compensated for the impairment of proteosomal 
activity246. This finding underscores the reciprocal interplay between these clearance systems3. 
Indeed, the ALN can “sense” UPS failure and compensates by upregulating its own activity. For 
example, proteasomal failure exacerbates ER stress and leads via the UPR to the expression of 
Sestrin-2 which recruits AMPK to down-regulate mTORC1 upstream of the ALN: Nrf2 is also 
upregulated3. Supporting the relevance of Sestrin-2, it protects dopaminergic neurons from the 
neurotoxin, rotenone, via AMPK-transduced autophagy247. Sestrin-2 overexpression also 
prompted mTORC1-dependent autophagy in cortical neurons in a presenilin-knockout model of 
AD248. Proteasomal degradation of Ulk1, LC3 and other ALN regulatory proteins may prevent 
ALN over-activity, an observation of particular relevance to ALS (Suppl Box 3)3. By analogy, 
subunits of the catalytic core of the proteasome are regulated by CMA-mediated 
degradation47,55. 
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Extracellular elimination of neurotoxic proteins and its impairment in NDAs  
Exosomal liberation of neurotoxic proteins from neurons 
When intracellular pathways of protection prove insufficient, neurons may alleviate the 
burden of harmful proteins by discharging them into the extracellular space. This may be a self-
preservation mechanism and an attempt to acquire glial support for elimination. However, the 
“release“ of neurotoxic proteins contributes to trans-cerebral spread of pathology. That is, 
abnormal conformers of proteins originating in donor cells enter recipient cells to promote protein 
misfolding and disrupt clearance, diffusing in a domino, snowball-like fashion across the 
brain81,249. 
Exosomes are involved in the release of tau, APP/A-42 and -synuclein. Accordingly, 
they are linked to the progression of NDAs 55,77,81,250,251. Intriguingly, when the ALN is 
overwhelmed and cargo accumulates, a process of “autophagic” exocytosis participates in the 
neuronal liberation of neurotoxic proteins. This discharge of neurotoxic proteins adds to the 
extracellular burden from dying cells, accelerates spreading, and underpins the imortance of 
clearance mechanisms extrinsic to neurons250,252.  In this light, capture and digestion of 
extracellular proteins by glial cells is primordial7,8. However, there exist several other, 
therapeutically-pertinent mechanisms for ridding the brain of extracellular pools of neurotoxic 
proteins. 
 
Clearance of neurotoxic proteins by proteases in the extracellular space 
Neurons and glia contain diverse classes of protease, and they are localized in all 
those compartments where neurotoxic proteins accumulate - cytosol, mitochondria and 
even the nucleus39,253-256. However, certain intracellular proteases in the cytosol generate 
toxic fragments, notably of tau (calpains and caspases) and Htt (matrix metalloproteinases 
(MMPs)39,257. Accordingly, their inhibition rather than induction is of interest for the 
treatment of disorders like AD and Huntington’s disease. Indeed, the inducible 
(extracellular) proteases most relevant to promoting neurotoxic protein clearance in 
NDAs are actively secreted by neurons and glia, located on exosomes and/or expressed on 
plasma membranes (Figure 1)254. They include several classes of MMP, neprilysin, insulin-
degrading enzyme (IDE) and plasmin253,256,258,259. 
A42 and amylin (a pancreas-derived, AD-associated protein found in brain) are 
substrates for degradation by IDE, which also irreversibly “traps” A42  and synuclein, 
preventing their aggregation and promoting ALN and UPS elimination259. Cerebral levels of IDE 
are reduced in early AD and in mouse models of AD while, mirroring AD amyloidosis, A42 
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accumulates in mice genetically depleted of IDE. In a vicious circle, A42 itself decreases IDE 
expression, although it may prompt its release from glia254,259. IDE also degrades and prevents 
the formation of -synuclein fibrils259. By analogy to IDE, neprilysin catabolizes A42 and its loss 
in mouse models of AD and patients alike also contributes to levels A42 accumulation253,256,260.  
Another Aβ42-degrading protease, plasmin, is derived from inactive plasminogen by the 
actions of tissue-type plasminogen activator (urokinase), which is used to treat stroke. It is 
secreted by neurons (and possibly glia) into the extracellular space. Like IDE and neprilysin, 
plasmin degrades Aβ42 and blocks Aβ42-induced toxicity, suggesting that the decrease in its 
levels in AD is involved in the evolution of AD254,256,261. Plasmin also degrades α-synuclein to 
retard intercellular spreading262.  
Interestingly certain isoforms of MMPs cleave fibrillar as well as monomeric A254while 
extracellular -synuclein is also a substrate for MMP-3256,258. Another protease with 
pharmacotherapeutic potential is angiotensin-converting enzyme which contributes, albeit less 
prominently, to degradation of neurotoxic proteins in NDAs263. Finally, the extracellular and 
intracellular serine protease, neurosin (kallikrein 6), cleaves -synuclein. Levels are reduced in 
Lewy body dementia and, based on lentivirus transduction studies, it is a potential treatment for 
clearing -synuclein in PD264. 
 
Clearance of neurotoxic proteins by the blood-brain barrier and the glymphatic system 
In AD, HD and other NDAs, disruption of the structure and function of the dynamically-
regulated BBB is driven, at least in part, by detrimental actions of neurotoxic proteins like 
A. This permits the otherwise-restricted entry of immune cells and toxic substances into the 
brain. In addition, the active elimination of neurotoxic proteins like A42 and tau (possibly 
encapsulated in exosomes) from the brain may be compromised (Table 1 and Figure 1)265-
273. 
Dysregulation of BBB integrity is serious since it normally transfers neurotoxic proteins 
to the circulation using both generalized and specialized receptors and transporters (Figure 1) 
265-267,270-272. In addition, proteins are degraded by vascular smooth muscle and endothelial cells 
of the BBB itself265,271,272. In ageing, AD and PD, a diminution of BBB-localized P-glycoprotein 
efflux transporters compromises elimination of neurotoxic proteins267,273. There are also 
decreases of low-density lipoprotein receptor-related protein1 (LRP1) transporters in AD, 
whereas receptor for advanced glycolation end-products (RAGE) receptors are induced. These 
changes would respectively contribute to retention in, and return of, Ato the brain270-272. An 
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ApoE4 genotype in AD exacerbates poor Aclearance by reducing its transport to the BBB 
and diminishing efflux270-272. 
Arterial pulsing aids CSF/ISF flow in flushing out interstitial extraneuronal proteins via 
the complementary glymphatic system (Figure 1)265,269,274,275. Its regulation is not well 
understood, but roles for aquaporin-4 water channels, other astrocytic mechanisms and 
noradrenaline have been documented265,276,277. Deletion of Aquaporin-4 in astrocytes markedly 
reduced glymphatic flow and aggravated A accumulation in a genetic mouse model of 
AD276,278 while aquaporin-4 expression is altered in the ageing, AD and PD brain276,277. Loss of 
sleep has been linked to an impairment of glymphatic clearance and A accumulation274. This 
is significant since “rapid eye-movement sleep-behavior disorder” is the most robust predictor of 
PD, while insomnia and anomolous sleep patterns occur in other NDAs like early-onset AD, 
where disrupted sleep is correlated with alterations in A levels279. 
 
Strategies for promoting extracellular clearance of neurotoxic proteins 
Increasing protease-driven degradation 
Overexpression of neprilysin or IDE reduces levels of A42 and amyloid plaque burden in 
senescence-accelerated mice256. As regards pharmacological manipulation, substances like 
epigallocatechin and somatostatin promote the expression, secretion and - allosterically - 
catalytic activity of IDE and neprilysin in parallel with an increase in the degradation of A 
peptides259,280. Further, expression of progranulin in the hippocampus of AD mice reduces the 
density of amyloid plaques by enhancing the activity of neprilysin281. Epigenetic regulation of 
neprilysin at the level of histones, as exemplified by valproate, offers another potential approach 
to proteolytic potentiation253. As regards other proteases, augmentation of plasmin clearance by 
blockade of the plasminogen inhibitor “PAI-1” (the expression of which increases with ageing 
and in murine models of AD) reduced Aβ levels and restored memory deficits in mouse models 
of AD261,282. 
These observations underscore the interest of proteases as targets for degradation of 
neurotoxic proteins253. Further, several drugs evoked above like resveratrol and curcumin induce 
IDE and/or neprilysin, suggesting a contribution to their actions253. Nonetheless, structure-activity 
relationships for small molecules that enhance the catalytic activity (or production) of proteases 
are not well-characterised253,283. Further, there are issues of substrate specificity. For example, 
IDE degrades insulin and glucagon as well as A42 and interacts with many other proteins, 
including the proteasome259. Neprilysin targets a range of substrates like atrial natriuretic 
peptides and substance P, and inhibitors are employed in the therapy of heart failure,253 while 
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MMP activators exert deleterious as well as beneficial effects reflecting their influence on 
microglia and the BBB258,284. Additional questions centre on whether any protease inducer alone 
could comprehensively and enduringly clear the burden of neurotoxic proteins in NDAs. 
Thus, further work is needed to determine to what extent potentiation of extracellular, glial 
and endothelial/BBB-localized proteases is a viable strategy for safely enhancing neurotoxic 
protein clearance in NDAs253,259. 
 
Immunotherapies for neurotoxic protein sequestration 
Immunotherapies for neurotoxic protein clearance in NDAs have been pursued for over 
a decade. As reviewed elsewhere81,285, the most advanced approach is currently antibodies for 
sequestering extracellular pools of A and tau (AD) or synuclein (PD)7,286. BBB antibody 
penetration is limited, but they may generate a “peripheral sink” in addition to exerting actions 
centrally. Although A-immunotherapy has not yet yielded an approvable treatment (examples 
being AN1792-NCT00676143 and bapineuzumab-NCT00112073), more refined cohort 
selection, amyloid imaging for selection of early-disease patients, and the use of monoclonal 
antibodies from human patients such as aducanamab (NCT01397539/02782975/02434718 in 
MCI, and recruiting for Phase III-NCT02484547/0247780) offers hope for progress287. 
 There are at least 5 antibodies under investigation for clearing tau, including a Phase II 
trial (NCT02880956) for C2N8E12 in AD288. Another trial (NCT02985879) is underway in post-
cerebral palsy employing a single-chain antibody. This is the second tau-based Phase II trial 
after AADvac-1 (NCT02579252) to use an active immunotherapy approach288. Passive tau 
immunity approaches are also being tested using the PHF1 (Ser396/Thr404) epitope (ACI-35; 
ISRCTN13033912) and Ser409 epitope (RG1600; NCT03289143)81,288. Targeting extracellular 
tau to block intercellular spreading249 should preclude the need for high antibody inclusion into 
cells. Antibodies like PRX002289 have also shown promise for reducing extracellular -synuclein 
and propagation of pathology, and Phase I testing has been completed (NCT02157714 and 
NCT02095171)285.  
Potential problems should not be ignored, including the deposition of immune-complexes 
in vascular tissue, inaccessibility of tau in exosomes, and antibody-driven import of A into the 
brain. Nonetheless, employing more effective antibodies and appropriate biomarkers, there are 
still reasonable prospects for achieving course-alteration with immunotherapy.  
 
Improving BBB-mediated and glymphatic transfer to the circulation 
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The BBB is equipped with potentially-targetable transporter proteins, channels and 
receptors (Figure 1)265-267,270-273. Inhibition of the -secretase, “ADAM10” was found to drive 
LRP1-mediated extrusion of A42 into the circulation290. In addition, LRP1 might be indirectly 
modulated by aquaporin-4 channels276-278 and epigenetically via miRNAs165. Further, the 
hydroxymethylglutaryl-coenzyme-A inhibitor, fluvastatin, upregulated LRP1 in the BBB to 
provoke A42 extrusion291. The antibiotic, rifampicin, likewise promoted A42 clearance by 
inducing BBB-localised LRP1 and P-glycoproteins273,292. Whether LRP1-driven uptake of A42 
by microglia (and hepatocytes) is involved in the favourable effects of LRP1 up-regulation 
remains to be clarified271. Interestingly, both fuvastatin and rifampicin have additional actions - 
including a probable induction of the ALN - that contribute to beneficial actions in models of 
AD291,293. As for RAGE receptors, their blockade should temper re-entry of A into the brain - and 
exert anti-inflammatory properties294,295. Phase III studies are underway with azeliragon 
(TTP488) in AD (NCT02080364; 02916056) following promising improvement in cognition in a 
Phase II trial296. Interestingly, resveratrol downregulated RAGE as well as MMP-9, actions 
related to decreased hippocampal load of A42297. Finally, at least in murine models of AD, 
agonists of retinoid-X receptors induce the BBB-localized P-glycoprotein “ABCB1” transporter, 
and this may account for bexarotene-mediated A clearance from the brains of AD mice298. Data 
with bexarotene remain controversial, but the principle of acting via BBB-localised transporters to 
encourage neurotoxic protein extrusion is clearly valid.  
Focused ultrasound therapy has mainly been used to enhance the entry of proteins and 
vectors into the brain. For example, siRNA probes for knocking down Htt or, in principle, genes 
encoding clearance-promoting mechanisms299,300. However, it acts bi-directionally, so CNS-to-
periphery transfer of neurotoxic proteins might likewise be accelerated. By targeting selective 
brain areas like the hippocampus/entorhinal cortex in AD, neurotoxic proteins could be driven 
into the periphery. Safety is obviously an issue, but it is reassuring that gap junctions close within 
6 hours or less301. 
Activation of aquaporin-4 channels on perivascular astrocytes to aid the glymphatic 
elimination of cerebral A and other toxic proteins is a potential strategy for stimulating 
clearance. Both antagonists as well as positive modulators have been identified, so this seems 
“chemically” feasible269,272,275,278. A contrasting approach is represented by dobutamine which 
stimulates arterial pulsation and the perivascular/glymphatic CSF flushing of neurotoxic proteins 
from the ISF via lymphatic conduits into the blood269,275. Deposition of A42 in cerebral vessels 
impairs vascular function-flexibility and is accompanied by an upregulation of 
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phosphodiesterase-3 in smooth muscle cells302. Cilostazol, a phosphodiesterase-3  inhibitor 
clinically approved for peripheral vascular disease (and an UPS activator), restored vascular 
reactivity, increased perivascular drainage of Aand promoted cognitive performance in a 
mouse model of cerebral -amyloidogenesis302. Intriguingly, a retrospective clinical analysis 
suggested that cilostazol (added onto dozenapil) abrogates cognitive decline in patients with 
modest dementia303. Adrenergic mechanisms influence ISF volume and hence neurotoxic protein 
clearance274, and additional pharmacological opportunities for promoting glymphatic efflux will 
likely emerge from an improved understanding of its regulation by astrocytic, neurotransmitter 
and other mechanisms269,272,274. 
Disruption of sleep impedes glymphatic clearance of neurotoxic proteins, so encouraging 
sleep hygiene should promote CSF/ISF transfer to the periphery274,275. The atypical 
antidepressant and sleep-promoting agent, trazodone, is of interest since it normalized an over-
protracted UPR and accordingly reversed pathology in animal models of tauopathies (Suppl 
Box 2)99. Other therapies that favour sleep in NDAs may improve glymphatic clearance of 
proteotoxic substrates and hence abate disease progression265,269,279. Interestingly, alcohol 
displays a J-shaped curve, with low/high consumption respectively enhancing/reducing 
glymphatic function - and moderating/aggravating the risk of dementia304. 
Finally, in a recent study in human subjects, peritoneal dialysis cleared peripheral A 
from the circulation, while parallel experiments in APP/PS1 mice showed that peritoneal dialysis 
reduced ISF and brain A load and ameliorated behavioural deficits305.  
  
Therapeutic perspectives and open questions 
 Accumulation of neurotoxic proteins unquestionably contributes to the onset and 
progression of NDAs. Accordingly, agents that promote their elimination are attractive as 
potential therapeutic agents. Nonetheless, several issues remain to be resolved prior to 
successful and safe clinical exploitation. 
First, improved knowledge of the causes, characteristics and chronology of poor 
clearance in NDAs, and of similarities and differences amongst them, would be important for 
clarifying which therapeutic strategy is best adapted to the treatment of specific classes of NDA 
and subsets of patients. This would also help determine the optimal mode, timing, pattern and 
dosage of treatment4.  
Second, it is important to better understand the interplay between neurotoxic protein 
clearance and other pathophysiological processes, such as neuroinflammation. Moreover, hub 
proteins like AMPK, mTORC1 and Sirtuin-1 impact both the ALN and manifold other processes 
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implicated in NDAs, such as epigenetic regulation and energy homeostasis21,24,25,306,307. Hence, 
drugs that modulate their activity may have beneficial and/or deleterious actions beyond their 
influence on clearance. Indeed, potential side-effects should not be ignored. This is exemplified 
by mTORC1 antagonists like rapamycin which possesses immune-suppressive actions and 
affect memory formation, although studies in oncology and neurodevelopmental disorders are 
reassuring5,307. 
 Third, numerous mechanisms remain to be pharmacologically harnessed. These include 
receptor tyrosine kinases for the ALN and “upstream” GPCRs potentially for all modes of 
elimination26,27,29. For the ALN, additional targets include the Vps34 complex, histone 
deacetylase-63, Rab proteins implicated in autophagosome-lysosome fusion186 and v-ATPase, 
crucial for lysosomal acidification40. There has been much recent progress towards manipulation 
of the UPS, whereas exploitation of the CMA remains a major challenge2,3,45-47,68,80. For certain 
targets, non-small molecule strategies like PROTACS, aptamers and RNA probes, as well as 
nanoparticles and nucleic acid-based therapeutics, may prove useful (Box 3). Novel 
technologies will also be of importance for achieving the specific clearance of neurotoxic vs 
“normal” proteins, and for directing actions to discrete cells and brain regions, like dopaminergic 
pathways in PD8,45. Further research is needed to confirm, clarify and potentially exploit the role 
of glymphatic clearance in the elimination of neurotoxic proteins in NDAs308. Another line of 
research could focus on the blood-CSF-barrier which bears parallels and differences to the BBB, 
is impacted in ageing, and also represents a potential site for acceleration of neurotoxic protein 
elimination: its contribution to clearance of A42 is diminished in AD269,272,309,310. 309,310 272. 
 Fourth, to improve the preclinical characterization of candidate medicine, we need more 
refined cellular and animal models, including induced pluripotent stem cells from patients (Box 
1)1,3,4,10,23. This will help to determine precisely which components of the ALN, CMA and UPS are 
impacted by specific classes of medication, and to quantify their influence on overall ALN flux. 
improved models should also help determine the influence of therapeutic agents on clearance in 
discrete classes of neuron in comparison to astrocytes and microglia, which may well require 
contrasting modes of manipulation. Improved models and measures should also facilitate 
the development of translational readouts for clinical trials. Studies of the multi-functional 
ALN promoter and aggregation inhibitor, methylene blue, exemplify challenges faced in 
patient selection, trial design, dose-response relationships, readouts of efficacy and 
optimal time of intervention (Suppl Table 1).  
 Fifth, improved clearance may well have a broad therapeutic time-window, yet early 
treatment would be advantageous, especially as regards reinforcement of the UPS and CMA 
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before aggregation predominates. Hence, reliable biomarkers of clearance will be important for 
detecting pre-symptomatic subjects for early intervention81,311. Biomarkers are likewise crucial for 
demonstration of target engagement and as surrogate signals of disease-slowing and long-term 
efficacy. While we cannot directly monitor ALN, CMA or UPS in human brain, quantification of 
CSF and plasma levels of neurotoxic proteins like A42 and tau is instructive. Further, imaging 
of neurotoxic protein load is helping enrollment of subjects into clinical trials311. In addition, retinal 
imaging offers a window on cerebral clearance of tau312 while biomarkers of neurovascular flow 
from the brain to the circulation are under development265,275. 
Sixth, the therapeutic strategies evoked herein are pertinent to other classes of NDA. For 
example, Machado-Joseph disease (spinocerebellar ataxia type-3) is an autosomal-dominant, 
polyglutamine disease provoked by over-repetition of a CAG sequence in the ataxin3 gene. The 
mutant protein destabilizes beclin 194. Accordingly, studies in transgenic mice and fibroblasts 
from patients suggest that reinforcing beclin 1-dependent ALN flux would be beneficial313,314. 
Blockade of mTOR1 to induce autophagy (and the UPS) may likewise be useful.  
Finally, reinforcing clearance might best be undertaken in association with other 
strategies like suppression of protein misfolding, amelioration of cerebral energetics, or 
moderation of neuroinflammation2,3,7,25,164,181,. Drug associations or multi-target agents 
possessing complementary mechanisms of action are both viable options. In addition, 
medication for promoting neurotoxic protein clearance will likely prove most effective when used 
in conjunction with lifestyle changes like improved sleep hygiene, exercise and a healthy diet. 
 
Concluding comments  
An excessive neurotoxic protein load is a core pathophysiological feature underlying and 
driving NDAs. Amongst several potential strategies for alleviating this burden, an enhancement 
of clearance is particularly attractive in view of the range of options available, and because 
insufficent elimination is itself implicated in the pathogenesis of NDAs. While challenges remain, 
ALN, CMA, UPS, proteolytic, neurovascular and lymphatic mechanisms of clearance offer 
potentially important strategies for preventing the onset and progression of diverse classes of 
NDA. Intensive work in this field will hopefully soon be translated into clinical benefits for 
patients. 
 
  
NRDD CLEARANCE TEXT AND BOXES RESUBMITTEDs 04 MAY 2018  33 
Acknowledgements 
 
The authors would like to thank San-Michel Rivet for help in the preparation of the Figures, 
Karen Duff, Ross Jeggo, Marie-Claude Potier and Clot Mannoury la Cour for helpful comments 
on the manuscript, as well as Muriel Galliot and her colleague in the IDRS Documention 
Department for provision of papers relevant to this article. This article is based upon a small, 
focused Congress which was supported by an unrestricted grant from ”Advances in 
Neuroscience for Medical Innovation”, affiliated to the Institut de recherche Servier.  
 
 
  
NRDD CLEARANCE TEXT AND BOXES RESUBMITTEDs 04 MAY 2018  34 
Glossary 
 
Neurodegenerative disorders of ageing (NDA): A suite of neurodegenerative diseases 
including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and 
frontotemporal dementia that typically are diagnosed in the elderly. Most cases are sporadic, but 
rare forms are associated with mutations (Table 1). Huntington’s disease is an exception in 
being purely genetic and having a somewhat earlier onset at 30-50 years of age. 
 
Proteinopathy: General term for disorders characterised by the buildup of excess, anomalously-
marked, misfolded and/or aggregated neurotoxic proteins like A, tau or -synuclein. 
 
Amyloid: The major neurotoxic product of APP processing, including amyloid, that deposits 
into extracellular plaques in Alzheimer’s disease. It is toxic as a soluble monomer or low-order 
oligomers by, for example, disrupting synaptic transmission, damaging mitochondria and 
impeding proteosomal clearance.  
 
Tau: A protein that stabilizes axonal microtubules. It is prone to cleavage, hyperphosphorylation 
and other modifications that trigger and/or follow microtubule dissociation. This leads to 
misfolding, oligomerisation, synaptic mislocalization and inter-neuronal spreading. Aggregates, 
fibrils and initracellular neurofibrillary tangles are also formed. 
 
-Synuclein: A phospholipid-binding protein abundant in pre-synaptic terminals and involved in 
the release and regulation of synaptic vesicles. -synuclein is a major component of Lewy 
bodies (protein and lipid aggregates) in PD. Its spread and accumulation in dopaminergic cell 
bodies and other cell types is a typical feature of the disease. 
 
TAR DNA Protein-43: A normally nuclear protein that is associated with FTD and ALS. In these 
diseases, it is found in the cytoplasm where it aggregates.  
 
Glymphatic System: CSF-driven mechanism for flushing extracellular pools of neurotoxic 
protein into the circulation: it involves perivascular drainage, astrocytes and the lymph system.  
 
Blood-brain barrier: Physical and functional barrier that isolates the brain from the rest of the 
body. Certain nutrients, lipid vesicles and small molecules enter, yet it excludes toxic elements 
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that may damage the brain. It also ejects neurotoxic proteins and other unwanted material. 
Active transfer of neurotoxic proteins from the brain to the periphery involves specific classes of 
receptor and transporter. 
 
Aggresomes: Microtubule-associated inclusions located in the perinuclear region that contain 
mainly oligomeric, aggregated and ubiquitinated neurotoxic proteins together with p62 and 
chaperones that aid in their formation. Often generated when UPS activity is insufficient. 
Protective when short-lived, yet may be harmful in the long-term and can morph into Lewy 
bodies in PD. Cleared by the ALN. 
 
Stress granules: Non-membrane enclosed, cytoplasmic agglomerates of ribonucleoproteins 
that store and protect mRNA during short-term cellular stress. Chaperones like Hsp70 are 
involved in assembly and unfolding. In NDAs, neurotoxic proteins prolong the presence of stress 
granules and decrease their solubility, leading to aggregation or transformation into aggresomes. 
 
Peroxisomes: Small (100nm-1M) organelles which oxidize long-chain fatty acids and aid in 
detoxification. They can be generated by budding-off the endoplasmic reticulum and replicate via 
fission. Pexophagy refers to the autophagy of peroxisomes. 
 
Lysosomes: An acidic compartment for the degradation of proteins and other cellular 
constituents. Their breakdown yields products like amino acids, sugards and lipids which are 
recycled. Christian de Duve received the Nobel Prize in Physiology or Medicine for their 
discovery in 1974. 
 
Autophagy-related genes: Genes and the molecular machinary for autophagy were 
characterised in yeast by Y. Ohsumi (Nobel prize in Physiology or Medicine, 2016) and others. 
The associated genes, identified using mutants, were originally termed Apg1-15, yet Atg is now 
used. In view of conservation across species, this terminology is used for genes/proteins that 
regulate autophagy in humans as well.  
 
AMP-kinase: 5'-adenosine monophosphate-activated protein kinase, an enzyme involved in 
energy and nutrient sensing. When activated, AMPK triggers glucose uptake, lipogenesis and 
triglyceride synthesis. It is a major protein for sensing ATP deficits and initiating the autophagic-
lysosomal network. 
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Mammalian target of rapamycin: Multi-tasking serine/threonine protein kinase that inhibits 
autophagy, mitophagy and proteosomal degradation. It also has other roles in, for example, 
controlling mRNA translation and protein synthesis. Comprises part of a complex (mTORC1) 
together with several other regulatory and effector proteins.  
 
Nicotinamide adenine dinucleotide: Dinucleotide co-enzyme necessary for energy generation 
in all types of cell. It is a co-factor for activation of Sirtuin-1, and is required for operation of the 
ALN. The oxidised and active form is NAD+. 
 
Acetyl coenzyme A: Cofactor involved in protein, carbohydrate and lipid metabolism. it is 
formed during glycolysis. It provides the acetyl used by acetyl transferases like p300 to acetylate 
Agt proteins, histones and other substrates like tau. 
 
Rab proteins: Members of the Ras superfamily of monomeric G-proteins that participate in 
vesicular trafficking, vesicle formation, vesicle movement (actin/tubulin-mediated) and vesicular 
fusion, as in autophagosomal fusion with lysosomes. 
 
SNARE: SNARE (Soluble N-ethylmaleamide-sensitive factor Attachment protein REceptor) 
refers to a complex of proteins including Synaptobrevin, Syntaxin, “SNAP-25” and 
Synaptogamin. SNARE contributes to vesicle fusion by “zippering” a donor vesicle (like an 
autophagosome) onto the recipient compartment (like the lysosome).  
 
Phospholipase D: Enzyme involved in the transformation of various lipids: it participates in the 
fusion of autophagosomes with lysosomes. 
 
Lysosomal storage disorders: Diseases resulting from genetic mutations that lead to failure of 
lysosomal digestion and consequent accumulation of lipids, proteins and other non-digested 
material. Pathology not restricted to the brain. Age of onset much earlier than for sporadic, age-
related neurodegenerative disorders. 
 
Niemann-Pick Type C disease: Lysosomal storage disorder triggered by a defect in the NPC1 
gene responsible for cholesterol transport. Patients often display A and tau pathology, 
underpinning parallels to AD in which cholesterol transport is likewise disrupted. 
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Hsc70: Hsc70 (Heat shock cognate 70kDa protein) is a constitutively-expressed 
chaperone also known as Heat Shock Protein Family A member 8 which effects ATP-
dependent nascent/unfolded protein folding. It specifically recognizes proteins with an 
exposed KFERQ-like sequence and delivers them to LAMP2A on lysosomes where, aided 
by other proteins, substrates are translocated to the lumen for degradation by CMA. 
 
KFERQ: The KFERQ motif on a protein is the principal criterion for capture followed by 
CMA. Q refers to glutamine - although this sometimes may be an asparagine (N). The 
other residues are acidic (D), basic (K, R) or basic/hydrophobic (F). There are, however, 
variations and post-translational modification can modify susceptibility of proteins 
bearing a KFERQ signal for CMA. 
 
Lipofuscin: Pigmented cellular inclusion composed of undigested lysosomal contents, including 
oxidised and cross-linked proteins. This electron-dense, autofluorescent material is characteristic 
of ageing and NDAs, and can be seen in all types of cerebral cell. 
 
Unfolded protein response (UPR): Protective response to help cells recover from cellular and 
ER stress. Acts via three key effector proteins to modify gene transcription/mRNA translation. 
The UPR interrupts bulk protein synthesis, promotes the generation of chaperones for protein 
folding, and increases degradation of misfolded proteins. Over-activation and protracted 
engagement of the UPR is harmful for neurons and implicated in NDAs. 
 
ALN dysfunction: Underactive autophagy - term used when rates of autophagosome formation 
and cargo sequestration decrease below basal levels, or fail to upregulate sufficiently under 
stress. Impaired autophagy - lysosomal delivery, fusion or digestion of autophagosomes is 
compromised. Overactive autophagy - over-production of autophagosomes and excess ALN 
activity: can lead to autosis. 
 
Autosis: Autophagy-mediated cell death mediated principally by the Na+/K+-ATPase pump. Can 
occur with prolonged and excessive autophagy. Triggered by hypoxia-ischemia (as in stroke or 
traumatic brain injury) but occurrence in NDAs is uncertain. 
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Apolipoprotein Epsilon 4 (ApoE4): Robust genetic risk factor for AD vs the more common 
ApoE2 and E3 alleles. ApoE is secreted by astrocytes and binds lipids like cholesterol which are 
carried to neurons. Also involved in transport of cholesterol-bound A to the blood-brain barrier 
(ApoE4 less efficient than 2/3), and in driving synthesis of AApoE4 more potent than 2/3). 
 
Presenilin-1: Catalytic unit of the -secretase complex that processes APP into -amyloid. 
Mutations are associated with familial AD, and in part reflect altered APP processing. In addition,  
reduced lysosomal acidification and ALN function may be involved due to mutant Presenilin-1 
driven deficits in maturation and translocation of vATPase subunits to the lysosome. 
 
Amyloid precursor protein: Transmembrane protein highly expressed in neurons and involved 
in maintaining cell-cell contact. Successive cleavage by - and -secretases results in the 
formation of APP terminal fragments like C99, as well as Aand related species of neurotoxic 
peptide. 
 
Parkin: Component of the E3 ubiquitin ligase complex that binds to its partner PINK1 to facilitate 
the autophagic removal of dysfunctional mitochondria that have lost their membrane potential.  
 
Gaucher’s disease: Primary, autosomal-recessive lysosomal storage disease caused by 
mutations in the GBA1 gene which encodes -glucocerebrosidase: 5-fold higher risk for PD in 
affected carriers. The activity of -glucocerebrosidase is impaired in a sub-population of non-
familial PD patients, many of whom show genetic mutations related to lysosomal disruption. 
 
Superoxide dismutase (SOD1): Mitochondrial enzyme dedicated to the reduction of free 
radicals (reactive oxygen species). SOD1 mutations and dysfunction are seen in a subset of 
patients with amyotrophic lateral sclerosis. 
 
CAG-expansion repeats: Proteins containing multiple CAG repeats - CAG encoding glutamine 
(symbol “Q”). When the number of CAG repeats is supra-normal (for example, >35 for Htt 
protein), proteins aggregate, provoke cellular damage and trigger inherited, polyglutamine 
(polyQ) diseases like Huntington’s disease, spinocerebellar ataxia 3/Joseph-Machado disease 
(ataxin-3 protein), and spinal and bulbar muscular atrophy (androgen receptor protein). 
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TAT-beclin 1: A synthetic peptide comprising 11 amino acids of the Human Immunodeficiency 
Virus Tat protein transduction domain, a diglycine linker and a (commonly 11-mer) sequence 
derived from amino acids 267–284 of beclin 1. Cell-penetrant and triggers ALN-mediated 
neurotoxic protein clearance without causing cytotoxicity, although higher concentrations may 
carry the risk of autosis. 
 
Heat Shock Factor 1 (HSF1): Protein that occurs as a monomer in the nucleus and cytoplasm, 
being repressed by heat shock proteins like Hsp70. Following disruption of proteostasis, heat 
shock proteins dissociate from HSF1 in order to aid protein-folding. HSF1 then trimerizes and 
acts as a transcription factor to increase production of Hsp70 and other neuroprotective proteins.  
 
Exosome: Small (30-150nm), ceramide-rich vesicles formed from cytosolic endosomes, 
multivesicular bodies and lysosomes. Released with contents (proteins, lipids, sugars and 
nucleic acids) into extracellular space upon fusion with plasma membrane. Contribute to spread 
of neurotoxic proteins. Exosomes in CSF, blood and urine are stable and useful as biomarkers.  
 
Immunotherapy: A “biological” therapy that passively or actively boosts the body's natural 
defenses. Specific classes of antibody aim to neutralise neurotoxic proteins like A or tau. 
Entrance to the brain is limited, but they may also act as a peripheral sink for neurotoxic proteins 
in the circulation. In the brain, antibodies probably act for the most part extrinsically to neurons. 
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Box 1: Autophagic-lysosomal flux and its measurement: cellular and animal models  
      Characterisation of the ALN and its therapeutic restitution in NDAs necessitates accurate 
interpretation of autophagic states both in vitro and in vivo10,23. While electron microscopy has 
traditionally been used to observe key features of autophagosomes, recently-introduced 
approaches allow for more refined analysis of the ALN: for example, whether increases in 
autophagosome number (the most common measure undertaken) reflect an increase in their 
synthesis or, rather, decreased ALN flux23. 
Since membrane-bound LC3-II (called Atg8 in zebrafish) is covalently conjugated to 
phosphotidylethanolamine on the outer and inner autophagosomal membranes (Figure 3), its 
expression and localisation is widely used to track autophagic kinetics. Calculating the ratio of 
LC3-II to tubulin is a popular method for measuring cellular autophagosome levels by 
immunoblot17. Green fluorescent protein (GFP)-tagged LC3 has proven especially useful for 
quantifying autophagosomes, but self-aggregation of cytosolic GFP-LC3 and the quenching of 
GFP fluorescence in acidic lysosomes complicates interpretation in cytological assays23. To 
overcome GFP quenching, tandem constructs containing GFP and an acid-resistant red 
fluorescent protein (DsRed or mCherry) can be used to discriminate autophagosomes (and 
amphisomes) from autolysosomes (Figure 3). To show that increased levels of LC3-II genuinely 
represent accelerated ALN flux, it is useful to use compounds like bafilomycin A or chloroquine 
which neutralise lysosomal pH and produce an additive elevation in LC3-II levels under 
conditions where ALN flux is indeed high. Levels of p62 or other cargo acceptors are also useful 
readouts: a decrease in p62 often accompanies accelerated autophagic flux, while its 
accumulation may indicate a decrease. Potential variables that complicate this measure include 
proteasomal degradation of p62, alterations in transcription and reduced protein synthesis in 
degenerating cells315. Therefore, parallel monitoring of p62 mRNA levels and UPS status is 
recommended229. Phospho-specific antibodies that detect activation states of key autophagy-
regulatory kinases like AMPK, mTORC1 and Ulk1 are also instructive indicators of ALN status.  
As regards in vivo models, Zebrafish (Dano rio) larvae are transparent and permit 
visualization of ALN reporters like GFP-LC3-II constructs and neurotoxic proteins316. Further, 
targeted gene transduction, deletion or editing can easily be performed by morpholinos and the 
“CRISPR/Cas” system. Comparatively high-throughput screening can also be undertaken with 
compounds added to water that are absorbed transdermally103. For example, stimulating 
autophagy and TFEB nuclear translocation by trifluoperazine prevented neuronal loss in PINK1-
deficient zebrafish317. Fruitflies (Drosophila melanogaster) are also useful. They can be rendered 
autophagy-deficient, resulting in spontaneous neurodegeneration, while restoration of autophagy 
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is neuroprotective in PINK1 mutants318. In addition, genetic tools are available for manipulating 
each step of ALN disruption, while somatic, mutant clones in subsets of specific neurons permit 
evaluation of ALN status in impacted cells surrounded by wild-type tissue319. Drosophila have 
also been used to validate the effects of drugs regulating the ALN: for example, rapamycin had 
beneficial effects in a polyglutamine model of HD133. Nonetheless, mice remain the most 
common, in vivo, pre-clinical model for modulation of the ALN in NDAs23 and a broad range of 
pharmacological agents has been studied, as summarized in Table 2. Apart from the brain, 
retinal tissue has also proven instructive: for example, in evaluating axonal transport of acidic 
vesicles to lysosomes312,320. 
 Finally, for in vitro and in vivo studies of the ALN, overexpression of mutant proteins 
associated with NDAs is often used as a model of proteinopathy burden. However, this may not 
faithfully recapitulate sporadic forms of disease and the importance of other factors influencing 
the ALN, like ER stress, the cytosolic and mitophagic UPR (Suppl Box 3) and diminished energy 
supply, should be borne in mind25,57,58,99,321. 
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Box 2. Defective mitophagy and its restoration for treatment of NDAs  
  
Mitochondria support the high energetic costs of a complex and dynamic neuronal 
architecture, synaptic transmission and, last but not least, operation of the ALN. Indeed 
mitochondrial function and the ALN are reciprocally interlinked. For example, generation of 
radical oxygen species and ATP depletion induce the ALN via AMPK which will, in turn, eliminate 
damaged mitochondria21,322. In fact, there are several quality control mechanisms that preserve 
healthy mitochondrial populations: fusion and fission cycles to redistribute mitochondrial content 
and isolate damaged mitochondria; chaperones for ensuring maturation and folding of 
mitochondrial proteins; proteases for degrading misfolded mitochondrial constituents; lysosome-
dependent pathways for destruction of damaged mitochondria; and a specific mode of UPR that 
preserves mitochondrial proteostasis57,255,323. 
Mitophagy refers to a type of macroautophagy that leads to degradation of mitochondria 
(Figure 2)9,70,323. While crucial for many developmental programmes, mitophagy has a more 
generalized, protective role in preventing the accumulation of reactive oxygen species and the 
release of pro-apoptotic factors. Of particular significance to NDAs is a stress-responsive, 
mitochondrial degradation cascade co-regulated by two genes known to be mutated in familial 
PD: the mitochondrial kinase, PINK1 and the E3 ubiquitin ligase, Parkin69,70. This cascade, 
driven by PINK1-dependent activation of Parkin and ubiquitylation of proteins in dysfunctional 
mitochondria, is a well-characterised pathway of mitochondrial clearance, and studies using 
fluorescent reporter systems to track mitochondria in autophagosomes and lysosomes have 
highlighted its important role in neurons324. PINK1 may also clear damaged mitochondria 
independently of Parkin by recruiting autophagy receptors like optineurin: for example, in AD 
where PINK1 appears to be deficient325. 
Whether driven by the PINK1/Parkin system or other ubiquitin-dependent or independent 
mechanisms, mitophagy decreases with age. Further, while mitophagy may be compensatorily 
augmented at the onset of NDAs, in later phases it is generally disrupted9,75,323. There is a 
complex interplay between protein aggregation, mitochondrial dysfunction and mitophagy. 
Aggregation-prone proteins, such as Aβ, SOD-1 variants and -synuclein are imported into 
mitochondria326. This may reflect an adaptive mechanism, using mitochondria to clear 
aggregates255. However, in the long run, aggregation-prone proteins like -synuclein provoke 
mitochondrial dysfunction and block mitochondrial protein import. Stimulating mitophagy may, 
thus, improve both mitochondrial function and cytosolic proteostasis58,255,326.  
As for pharmacological approaches for promoting mitophagy in NDAs327, certain are common 
to those inducing cytosolic autophagy. More specifically, several strategies aim to activate 
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PINK1/Parkin-driven mitophagy, for example, by the neo-substrate, kinetin triphosphate, which 
enhances PINK1 kinase activity328. Small-molecule transcriptional activators of Parkin have also 
been proposed329. Other approaches use iron chelators to induce PINK1/Parkin-independent 
mitophagy. The ubiquitin-specific deubiquitinase, USP30, negatively regulates the initiation of 
Parkin-mediated removal of damaged mitochondria: its structurally-distinct features compared 
with other deubiquitinases are encouraging interest as a Parkin-related drug target227,330. Two 
other deubiquitinases, USP8 (delays Parkin binding to damaged mitochondria) and 
USP15 (suppresses Parkin-driven mitophagy) are also under scrunity as targets for 
promoting mitophagy in NDAs217. 
The inner mitochondrial membrane protein, prohibitin-2, directly binds LC3-II to target 
ruptured mitochondria for degradation and is depleted in human PD brain11. Since Prohibitin-2 
overexpression is protective in cellular models of PD, it is an interesting target for potential 
therapy331. Compounds that stabilise Nrf2 are also of interest, since Nrf2 triggers Parkin-
independent mitophagy by a mechanism involving activation of p62332. Replenishment of 
nicotinamide, which declines with age56, may promote mitochondrial clearance by activating 
Sirtuin-1 driven mitophagy333. Further, in promoting mitochondrial proteostasis, nicotinamide 
derivatives opposed the deposition of Aβ in cellular and mouse models of AD58. The plant 
flavanol, kaempferol, induces autophagy and exerts protective effects on mitochondria, for 
example against toxins triggering PD-like dysfunction. Its actions involve induction of Akt 
upstream of mTORC1334. Other natural compounds, such as urolithin A, promote mitophagy by 
mechanisms that remain to be determined335. Finally, lifestyle factors, like exercise and 
intermittent fasting, favour mitochondrial and neuronal health by a combination of mechanisms 
that include the stimulation of mitophagy9,25,164,207.  
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Box 3: Novel, non-small molecule strategies for enhancing neurotoxic protein clearance  
 Classical ”small molecules” cannot explore all potentially-available chemical space and 
may not be suitable for some targets like protein-protein interfaces and lipids. They are also not 
ideal for discrete delivery to specific brain regions. Thus, it is important to outline a suite of novel, 
non-small molecule approaches for eliminating neurotoxic proteins in NDAs. 
Protein-protein interactions like Beclin-Bcl2 can be disrupted by a “Tat” strategy that 
homes in on a unique peptide sequence in one protein partner, and incorporates the addition of 
a short, basic, arginine-rich sequence to improve cell penetrance. A Tat-Beclin 1 construct 
triggered autophagy and cleared polyglutamine expansion protein aggregates in vitro174, while 
also promoting long-term memory in rats336.  
Aptamers are small oligonucleotides that recognise specific proteins. They offer another 
chemically-distinctive strategy for modulating clearance. Using this technology, the de-
ubiquitinase, USP1449,217 could be inhibited to facilitate tau clearance214. Inhibiting ubiquitin 
carboxyl-terminal hydrolase37, another proteosome-linked de-ubiquitinase, may also facilitate 
proteasomal clearance of neurotoxic proteins337. Similarly, aptamers moderated the ALN burden 
by blocking the misfolding and oligomerisation of tau338 and -synuclein339. 
Numerous classes of miRNA are deregulated in NDAs165, including an increase of miR-
34a in AD which neutralizes mRNAs encoding Sirtuin-1 and TREM2165. Conversely, miR-132, 
which likewise interacts with Sirtuin-1, is down-regulated in AD165. Another example is the loss of 
miR-124 in a lesion model of PD340. Selective targeting of miRNAs in NDAs is becoming possible 
using modified oligonucleotides like antagomiRs, locked nucleic acids and miRNA sponges165. In 
addition, stabilized antisense oligonucleotides are showing promise not only for silencing 
miRNAs like miR-34, but also for knocking out or altering the aberrant splicing of specific 
neurotoxic/aggregating protein like tau, mutant Htt, CRorf72 and SOD1341. 
PROTACs permit selective proteosomal elimination of unwanted proteins. They are 
composed of two motifs joined by a linker: one recognises a specific protein like tau236, whereas 
the other encodes an E3-ligase binding site234. This allows the target protein to be poly-
ubiquitinated, captured and degraded by proteasomes (and the ALN): addition of TAT-like motifs 
can increase efficacy234. In the 3XTgAD mouse model, PROTACs moderated levels of tau in the 
cortex and hippocampus suggesting target engagement in key pathological regions234. 
Interestingly, PROTACs may also be useful for orienting proteins towards CMA since the E3-
ligase binding site can be substituted by a “KFERQ” CMA-recognition motif. This approach was 
used to clear -synuclein in vitro233. Smaller PROTAC variants offer improved stability, higher 
potency and better structure-activity relationships342.  
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Restoring lysosomal acidification using poly(DL-lactide-co-glycolide) acidic nanoparticles 
proved neuroprotective in preclinical models of PD343 Though they are poorly brain-penetrant, 
nanoparticles with improved pharmacokinetic profiles are being developed. Encouragingly, 
intranasal delivery reduced 6-hydroxydopamine-induced neurotoxicity in rats344. Another 
dimension of nanotechnology is represented by engineered nanorods which, when internalized 
by Hela cells, accelerated the ALN and cleared Htt aggregates in synergy with trehalose via a 
mTORC1/ERK-signalling pathway: in vivo actions and safety remain to be established345. 
One strategy for locally enhancing intracellular clearance is virally-produced gene 
delivery to the pathological site, avoiding autophagic induction in “healthy” areas346. A target 
protein might be expressed in restricted areas using neuronal-type-specific promoters, like the 
dopamine transporter in dopaminergic neurons347. Invasiveness of delivery is a drawback, but 
peripheral administration employing exosomes together with the use of focused ultrasound to 
favour local BBB passage may offer a solution348. The latter approach enhanced access of 
siRNA to the striatum for knocking down mutant Htt300. Further, localised clearance was 
achieved with striatal lentivirus transfer of the proteasome activator, “PA28”, that binds the 20S 
subunit to form an immunoproteasome. It enhanced clearance and improved motor performance 
in an Htt mouse model349. Another example is provided by intranigral gene delivery of Beclin 1 or 
TFEB that stimulated the ALN and alleviated pathology in -synuclein overexpressing mice350.  
Finally, recurrent exposure of mice to a non-invasive, 40Hz flicker regime that entrained 
GABA interneuron-driven oscillations in visual cortex reduced A40/42 load: this resulted from a 
suppression of amyloidogenesis and a shift in microglial activation status leading to enhanced 
uptake and clearance351.  
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Figure 1: Overview of intra and extracellular mechanisms for the clearance of neurotoxic 
proteins from the brain.  
Neurotoxic proteins (NTPs) are eliminated by a broad suite of specific and non-specific 
mechanisms expressed in neurons, glial cells and endothelial/vascular smooth muscle cells of 
vessels. The three major modes of intracellular clearance are shown for neurons, but they are 
also active in other cells like microglia (“clearance”). Under conditions of inflammation, 
proteasomal -subunits in glia are switched and substrate specificity changes: the precise role of 
these ”immunoproteasomes” - specialized in peptide production for antigen presentation - for 
neurotoxic protein elimination in NDAs is debated8. Clearance also occurs in the extracellular 
space, the interstitial fluid (ISF) of the brain parenchyma that surrounds neurons, and the CSF 
with which the ISF exchanges. Intraneuronal mechanisms of clearance are illustrated for 
NTPs in general, but only Ais shown for extracellular clearance, since it has 
generated the vast majority of currently available data. Extracellular pools of NTPs are 
derived from passive diffusion, active release from terminals, extrusion by exocytosis, 
and dispersion upon cell death. NTPs disrupt neuronal and synaptic function and are taken up 
by other neurons and glial cells (“spreading”). Therapeutically-relevant proteases degrading 
NTPs include endothelin-converting enzyme and insulin degrading enzyme (IDE) (mainly 
cytosolic), neprilysin and matrix metalloproteinases (MMP) (intracellular and extracellular), and 
plasmin (mainly extracellular). NTPs that escape glial capture and proteases are driven into the 
circulation. First, blood-brain barrier (BBB) localised receptors and transporters actively eject 
them into the blood, including P-glycoproteins like “ABCB1” transporters and low-density 
lipoprotein receptor related protein 1 (LRP1). Conversely, the Receptor for Advanced Glycation 
End-product (RAGE) receptor returns Ainto the CNS. Similar mechanisms operate at the 
blood-CSF-barrier in the choroid plexus; for example, LRP2 transfer of transthyretin-bound 
Afrom CSF into blood. Second, transfer of NTPs to the periphery is mediated through the 
glymphatic system. CSF runs along the peri-arterial space, transverses Aquaporin 4 receptor-
bearing circumvascular astrocytes to enter the ISF. Convective flow driven by arterial pulsing 
flushes NTPs via glial cells and the peri-venous space back into the CSF. Glymphatic-cleared, 
CSF-derived NTPs mainly reach the circulation mainly via the cervical lymph nodes, but also via 
the dural venous sinus. Within the blood, specific proteins sequester A, such as the soluble 
fragment of LRP1 and immunoglobulins (IgG). NTPs are ultimately eliminated in the kidneys and 
liver. Abbreviation not in main text or above: s, soluble. 
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Figure 2: Overview of intracellular mechanisms for the elimination of neurotoxic proteins 
from neurons and other classes of cell in the brain.  
 Within neurons and other classes of cell, the UPS and CMA clear non-aggregated forms 
of neurotoxic protein, and the UPS also deals with substrates of Endoplasmic Reticulum 
Associated Degradation of incorrectly-folded proteins (“ERAD”). Proteins destined for the 
proteasome are poly-ubiquinated and guided to the proteasome by chaperones. They are 
deubiquinated by Rpn11 once committed to entering the proteosome pore: other  
deubiquitinases like USP14 may rescue them before entry49. Unfolding is followed by 
degradation. The CMA operates on proteins bearing a KFERQ-like motif. This sequence is found 
in, for example, tau but not A. Hsc70 recognises the KFERQ sequence and, together with co-
chaperones, transports the protein to the LAMP2A receptor on lysosomes: LAMP2A then 
coordinates protein translocation into the lumen. The ALN is the major system for removing 
misfolded, higher-order, aggregated proteins as well as damaged organelles. Autophagosomes 
bearing cargo fuse with acidic lysosomes leading to degradation of contents. In addition, some 
autophagosomes fuse with late endosome. The resultant amphisomes then likewise fuse with 
lysosomes. See also Figure 3. Abbreviation not in main text: Co-chap, co-chaperone; Lys, lysine 
and Ub, ubiquitin,  
 
Figure 3 Organization, operation and regulation of the autophagic-lysosomal network 
The top part of the schema illustrates the sequence of steps associated with operation of 
the ALN, while the bottom part shows the main regulatory proteins involved, focusing on 
potential targets for pharmacotherapy. “Sensing”, both extrinsic (e.g. glucose levels) and intrinsic 
(e.g. ATP/AMP levels), can determine whether or not autophagy is initiated by activation of 
AMPK and/or inhibition of mTORC1 - which leads to TFEB-driven transcription of ALN-requisite 
proteins. The pre-autophagosome (phagophore) structure first emerges from diverse membrane 
sources, and its formation is promoted by Atg9 (not shown). Nucleation is accomplished with the 
help of a complex cluster of proteins. Phosphatidylinositol-3-phosphate (PtdIns3P) is recognised 
by WIPI (WD-repeat-protein-interacting-with-phosphoInositides) proteins that help induce 
autophagosome elongation in association with several classes of Atg protein and small GTPases 
like Rab5. With the aid of LC3 and cargo acceptors, autophagosomes take up cytoplasmic 
material like aggregated proteins and dysfunctional mitochondria (Box 2). Autophagosomes and 
other autophagic vesicles are transported with the help of dynactin and dynein along 
microtubules towards acidic lysosomes. Autophagosomes fuse with lysosomes containing 
resident hydrolases that degrade their contents into amino acids, sugars and lipids etc for 
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recycling. Exosomal release/secretion of neurotoxic proteins (“exocytosis)”) may occur  upon 
reduced ALN flux and accumulation of autophagosomes. For details, see main text. 
Abbreviations not in main text or Glossary: FIP, family interacting protein; HOPS; Homotypic 
fusion and protein sorting complex; NAD+, nicotinamide adenine dinucleotide; PE, 
phosphoethanolamine; PI3K/Akt: phosphoinositol-3-kinase/atypical kinase and PLD, 
phospholipase D. 
 
Figure 4: Major molecular sites of action of agents that enhance neurotoxic protein 
clearance in NDAs  
Representative agents are shown for diverse modes of intracellular (ALN and UPS), 
extracellular (immunotherapy and protease-driven) and vascular (BBB extrusion and glymphatic) 
clearance. The principal loci of drug actions are depicted, yet precise mechanisms of action 
remain to be more fully deciphered for many drugs while several agents like resveratrol act at 
multiple sites (main text). As illustrated, a broad range of drugs exert their actions via AMPK, 
mTORC1 or sirtuin-1 (which also influences downstream events like autophagosome formation). 
Certain agents exert their effects via other components of the ALN, up to and including 
lysosomal catabolism. In addition, ambroxol acts as a chaperone to help transport 
glucocerebrosidase to lysosomes. Diverse class of agent likewise promote UPS activity, 
including chaperones that assist in protein refolding and triage, modulators of proteasomal 
phosphorylation, and agents acting via the transcription factor, Nrf2, to induce coordinated 
synthesis of proteasomal subunits. Extraneuronal clearance of full-length, truncated, post-
translationally-modified, monomeric and/or higher-order neurotoxic proteins can be promoted by: 
stimulating proteases like neprilysin; immunotherapies targeting specific neurotoxic proteins; and 
increasing BBB-mediated and glymphatic extrusion into the circulation. For details, see main 
text. Abbreviations not in main text or Figure 3: AT, acetyl transferase; DUB, deubiquitinase; 
GBA; glucocerebrosidase; G-synthase, glucoceramide synthase; PDE, phosphodiesterase; 
PKA/G, protein kinases A/G and RAR, retinoid acid receptor. 
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Table 1: Neurodegenerative disorders of ageing: major clinical and pathophysiological features, disruption of proteostasis, and impairment of 
neurotoxic protein clearance.  
Clearance mechanisms are recruited early in disease, yet eventually become dysfunctional and/or inadequate to cope with neurotoxic burden. Not all changes 
can be shown, and NDAs are associated with neuroinflammation/immune deregulation, glial anomalies, disruption of cerebral bioenergetics, mitochondrial 
dysfunction and ER/oxidative stress. Several variants of frontotemporal dementia (FTD) include behavioural, progressive non-fluent aphasia and semantic forms.  
ALS shares common pathological hallmarks and risk genes with FTD like C9orf72 (Chromosome 9 Open Reading Frame 72). This and other NDA-associated risk 
genes linked to impaired clearance, are indicated in column one. Examples of genes/proteins incriminated in pathological processes are given in columns 3-6. 
APOE4 (apolipoprotein E4); PARK9 (ATPase13A2); CHMP2B (chromatin-modifying protein 2B); DCTN1 (dynactin); FUS (Fused in sarcoma); GBA1 (-
glucocerebrosidase); GRN (progranulin); HTT (huntingtin); LRRK2 (leucine-rich repeat kinase 2); MAPT (microtubule association protein, tau) ; OPTN (optineurin); 
PARK2 (parkin); PICALM (phosphatidylinositol binding clathrin assembly protein); PINK1 (PTEN-induced putative kinase 1); PS (presenilin); SNCA (synuclein); 
SOD1 (superoxide dismutase 1); SQSTM1 (sequestome 1, p62); TBK1 (TANK-binding kinase 1); TARDBP (TAR DNA binding Protein 43); TMEM106, transmembrane 
Protein 106B; TREM2 (triggering receptor expressed on myeloid cells 2); UBQLN2 (ubiquilin 2); UCH-L1, Ubiquitin carboxy-terminal hydrolase L1 (a 
deubiquitinase) and VCP (valosin-containing protein). A refers to A42 and related neurotoxic fragments of APP. See text for further information and citations. 
Abbreviations not above or in text: FKBP, FK-binding protein; SNPC, substantia nigra, pars compacta and RBD, rapid eye movement sleep behavioural disorder.  
 
Disease 
(age of onset) 
 
% Familial 
 
Main risk genes 
related to poor 
clearance 
 
 
Clinical and 
pathophysiological 
 phenotype  
 
 
Disruption  
of proteostasis 
 
 
 
Autophagic-lysosomal 
network impairment  
 
 
 
Impairment of  
CMA and of the UPS 
 
 
Impairment 
in other modes of 
neurotoxic protein 
clearance  
Alzheimer’s 
(usually over 70) 
 
 ca. 5% 
 
APOE4, APP, PS1, 
PICALM, TREM2 
Cognitive deficits; 
psychiatric symptoms; 
disorganized language; 
disrupted sleep/circadian 
rhythms. Neurodegener-
ation (entorhinal cortex, 
medial temporal lobe, 
hippocampus etc); axonal 
transport; axonal and 
synaptic degeneration; 
altered microglial 
phenotype. 
Aoligomers disrupt neurones, 
synapses, aggravate tau toxicity; 
A aggregates in extra-cellular 
plaques/vessels; aberrant tau 
cleavage, post-translational 
marking, folding and 
oligomerisation; tau release 
and spreading; intra-cellular tau 
tangles (with p62 and other Ub-
proteins). -syn neuropathology 
in subpopulation. 
Sirtuin-1; Neuronal ALN flux; 
Autophagosome maturation, 
transport (MAPT) and fusion 
with lysosomes; APP loading 
(PICALM); APP and C-terminal 
fragment accumulation in endo-
lysosomes; Lysosomal acidity 
and digestion (PS-1/2, APP 
ApoE4); Glial ALN (TREM2, 
ApoE4). Mitophagy (PS1). 
 CMA (disrupted by 
A/tau aggregates); 
Anomalous mutant 
tau at LAMP2A 
impedes CMA;  UPS 
clearance (perturbed 
by A and tau 
oligomers); FKBP51 
binds Hsp90 to 
interfere with UPS 
substrate loading. 
Proteolytic A clearance 
(IDE, Neprilysin, Plasmin); 
BBB clearance of A and, 
probably, tau (LRP1; P-
glycoprotein; RAGE); A 
provision to BBB (ApoE4); 
glymphatic clearance of A 
and, probably, tau. 
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Parkinson’s 
(usually over 60) 
 
ca. 5-15% 
 
SNCA, PINK1, GBA, 
PARK2, LRRK2, 
PARK9, UCH-L1 
Motor impairment (poor 
gait, rigidity, bradykinesia, 
tremor); olfaction; 
gastrointestinal problems; 
cognitive deficits; pain; 
depression; prodromal 
RBD. Neuronal loss 
(Dopaminergic cells in 
SNPC etc). 
Syn inclusions and Lewy 
Bodies (contain lipids, syn, 
Tau, other neurotoxic proteins, 
ubiquitin); -syn release and 
spreading in brain - possibly 
earlier, in gut. Tau 
neuropathology in 
subpopulation. 
Many syn related anomalies 
of ALN: ATG9 mislocalisation; 
Formation, maturation, axonal 
transport and lysosomal fusion 
of autophagosomes;Lysosomal 
function (LRRK2, PARK9, GBA); 
beclin 1 (LRRK2); Mitophagy 
(PINK1, PARK2). 
LAMP2A/Hsc70 
levels;   CMA activity 
(aggregated -syn and 
mutant forms of -syn 
and LRRK2 block); 
Slow -syn dissociation 
from LAMP2A.UPS 
clearance (aggregates 
and mutant forms of 
-syn block); Impaired 
-syn traffic to UPS 
(UCH-L1). 
BBB -syn clearance; likely 
-syn elimination by 
glymphatic system. 
 
Frontotemporal 
dementia 
(~40-60) 
  
ca 10-15% 
 
MAPT, C9ORF72, 
GRN, VCP, FUS, 
TARDBP, TREM2, 
CHMP2B, 
TMEM106, 
UBQLN2 
Cognitive impairment; 
altered personality; mood 
and language deficits; cell 
loss prominently in inferior 
frontal and anterior 
temporal cortices, 
asymmetrically or 
bilaterally.  
Misfolded and aggregated 
forms of tau, TDP-43 and/or 
(more rarely) FUS; Often found 
with p62 and ubiquitin in 
inclusions. 
 
 
Autophagosome accumulation; 
Cargo loading into 
autophagosomes by p62; 
Axonal autophagosome 
transport (MAPT); Endosomal 
trafficking (CHMP2B); Lysosomal 
dysfunction (GRN, TMEM106); 
Glial ALN flux (TREM2). 
CMA and UPS 
clearance (impeded by 
aggregates of tau, TDP-
43 and FUS); poly-GA 
aggregates (caused by 
C9orf72 mutations) 
sequester and stall 
proteasomes; p62 
dysfunction. 
Not well defined, but likely 
similarities to AD as regards 
altered BBB permeability 
and  glymphatic flow. 
 
Amyotrophic 
lateral sclerosis 
(~50-60) 
 
ca 10% 
 
SOD1, TARDBP, 
FUS, C9ORF72, 
VCP, SQSTM1, 
UBQLN2, OPTN, 
TBK1, DCTN, GRN, 
TREM2 
Motor impairment 
(cramps, muscle weakness, 
spasticity); cognitive 
impairment; mood 
disturbances (especially 
late-phase); ventral horn 
motoneuron loss; 
brainstem and cortical 
neuron degeneration. 
Misfolded and aggregated TDP-
43 and (more rarely) SOD1 and 
FUS inclusions in brain, spinal 
cord and motoneurons; 
inclusions may contain ubiquitin 
and ubiquitin-ligases. 
 
Mainly ALN, but if cellular stress 
severe, high ALN may actually be 
detrimental; Autophagosome 
maturation (C9ORF72); Cargo 
loading (SQSTM1, UBQLN2, OPTN, 
TBK1); Autophagosome 
retrograde transport (DCTN, 
C9ORF72); Lysosomal function 
(CHMP2B/GRN); Glial ALN flux 
(TREM2). 
Aggregated proteins 
block proteasome; 
Hsp70 and Hsp40;  
Provision of SOD1 and 
other proteins for UPS 
degradation (VCP); 
  CMA clearance of 
TDP-43. 
 
BBB disruption; glymphatic 
flow may impede efflux of 
neurotoxic proteins.  
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Huntington 
(~30-50) 
 
Inherited 
 (ca. 8-10% = de 
novo mutations)  
 
HTT 
Motor dysfunction 
(chorea, dystonia, slurred 
speech); cognitive 
impairment; sleep 
disturbances; basal ganglia 
neuron loss, especially 
striatal medium spinal 
neurons; disruption of 
corticostriatal pathway; 
failure of axonal transport. 
Aggregates of mutant (excess 
CAG repeat number) Htt; 
mutant Htt inclusions with 
ubiquitin, beclin 1, mTOR1, p62 
and other cargo-loading 
proteins; Mutant Htt and 
fragments of Htt are cytotoxic. 
 
Mutant Htt poor substrate of 
and disrupts ALN - and 
mitophagy; interference with 
beclin-1; Autophagosome 
formation and cargo 
recognition/loading; Axonal 
transport of autophagosomes. 
Mutant Htt poor 
substrate of CMA and 
UPS; LAMP2A and 
Hsc70 initially 
upregulated, but CMA 
less efficient in late 
stages;  
Possible  UPS 
(blocked by mutant 
forms of Htt?); 
Hsp70. 
BBB disruption due to 
accumulation of Htt, but role 
in Htt clearance uncertain; 
potential glymphatic 
clearance to establish. 
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Table 2: Pharmacotherapeutic strategies for promoting intracellular clearance: actions in cellular and animal models of neurodegenerative 
disorders of aging.  
↓Indicates reduced, and ↑ increased levels. Cell line/species is followed by drug action in procedure/model. SK-N-SH, its sub-line SH-SY5Y and M17 are human 
neuroblastoma cell lines, H4 is a human neuroglioma cell line, and RPE denotes human retinal pigmented cells. Pheochromocytoma-12 (PC12) and neuro 2a 
(N2a) are mouse neuroblastoma cell lines, while HT-22 is a mouse hippocampal cell line. Cells were transfected with mutant protein, treated with A peptides, 
or exposed to cytotoxic stressors like serum deprivation, okadaic acid (phosphatase inhibitor), rotenone (mitochondrial complex I inhibitor), staurosporine 
(protein kinase A/C inhibitor), hydrogen peroxide (H2O2), lipopolysaccharide (pro-inflammatory) or prostaglandin J2 (neurotoxic). Mutant protein variants in 
superscripts: e.g., SynA53T. YFP signifies yellow-fluorescent protein tagged (fluoresce when oligomerised). For in vivo models, Table shows overexpression of 
mutant neurotoxic proteins, in some cases tagged with Green Fluorescent Protein (GFP) for visualization. Models employing transgenes and/or mutations 
(superscript) listed as, e.g., R6/2-Htt150. Transgenic models for polyglutamine disorders express pro-aggregant proteins bearing multiple CAG repeats. For example, 
the R6/2 HD mouse expresses exon 1 of the human HTT gene containing 144-150 CAG repeats. In a model of Joseph-Machado disease, mice overexpressed 
Ataxin 3(Q70)) with 70 CAG repeats. TDP43 and FUS (Fused in Sarcoma) refer to mice overexpressing these proteins as models for FTD and/or ALS. FLTD-U mice 
show Ubiquitin-inclusions upon TDP43 overexpression. The SOD1 mutant mouse, G93A, is a model of ALS. Tau (MAP gene)-based models related to FTD (and AD) 
include mice with P301L (JNPL3 line) or P301S (PS19 line) mutations. RTg4510 mice have regulatable tau (P301L) expression. HTau signifies overexpression of 
human, wild-type tau. Mouse models for AD are based on overexpression of Tau and/or APP (Swedish and Swedish/Indiana) mutations: Tg2576 mice 
overexpress mutant APP (isoform 695) with the Swedish mutation (KM670/671NL); J20, TgCRND8 and Tg19959 mice overexpress mutant APP with Swedish plus 
Indiana (V717F) mutations; APP/PS1 mice bear APP-Swedish plus PS1-L166P mutations; 3XTgAD mice contain 3 mutations (APP-Swedish, PS1-M146L and tau-
P301L) and 5XFAD mice encode 3 APP mutations (Swedish, Florida and London) plus 2 PS1 mutations (M146L and L286V). Models for PD are overexpression of 
wild-type or mutant (A53T, A30P) human synuclein, in one case on a -syn knockout background (SNCAKOtm1Nbm). R275W is a mitophagy-linked Parkin 
(PARK2) mutant mouse. GBA (glucocerebrosidase) mice embrace lines with natural (N370S and L444P) and induced mutations (D409V). Lesion-based models 
of PD employed the dopaminergic neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), okadaic acid or H2O2. Abbreviations not above or in text: 
CaMKK2, Calmodulin Kinase Kinase 2; DA, dopaminergic; HAT, Histone acetyl transferase; MAP Kinase, Mitogen Activated Protein Kinase; MCI, Mild cognitive 
Impairment; PE, phosphotidylethanolamine; PrP, prion protein; PS, presenilin; and PtdIns, phosphatidyl-inositol-3-kinase. 
 
 
Agent  
 
Clinical indication (or other use), and mechanistic 
influence on clearance mechanisms 
Influence on neurotoxic 
proteins: In vitro procedures  
Influence on neurotoxic proteins: 
In vivo models 
Autophagy activators: modulation of sensing, initiation and regulation 
AMPK facilitation 
Antihypertensives 
2-adrenergic agonists/AC inhibition, 
↓AC-AMP/↑AMPK  
PC12: ↓-syn (Syn A53T) / 
↓Htt (HttQ74)103 
Mice: ↓Htt, ↑motor function (Htt82Q)104 Clonidine, 
Rilmenidine 
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Calpastatin, 
 Calpeptin 
Investigational compounds 
(endogenous peptides) 
Calpain inhibitors:  
 ↑AMP/AMPK induction, ↓ cleavage 
Atg proteins 
SK-N-SH: ↓Htt (HttQ74)103  
Drosophila: ↓Htt, 
↓neurodegeneration (HttQ46)54 
Mice: ↓Htt aggregates, ↑motor 
function (Htt171-82Q)54; 
↓motoneuron loss (SOD1G93A)107, 
↓tauopathy (JNPL3-MAPTP301L)106 
AICAR 
Experimental agent. 
 Potential treatment for 
myocardial ischaemia 
AMP analogue - 
allosteric inducer of AMPK 
N2a: ↑AMPK108; Glia: 
↓toxicity(ALPS)109;  SH-SY5Y: ↓-
syn (wild-type protein)110 
- 
A-769662 Experimental agent 
Allosteric AMPK inducer 
 
Striatal neurones/mouse fibroblasts: 
↑LC3 and p62, ↓mHtt and ↑cell 
viability111 
- 
Resveratrol 
Polyphenol found in grapes 
etc (dietary supplement). 
Clinical evaluation in AD, MCI 
CaMKK2 potentiator, upstream of 
AMPK; Upstream inducer of Sirtuin-1 
N2a: ↑AMPK108; ↓AAPP695)114;  
Cortical neurones: ↓A(J20)114 
C. elegans: ↓polyglutamine (HttQ128)115; 
Mice: ↓A (APP/PS1)114 
Metformin 
Antidiabetic. 
Clinical evaluation for MCI 
AMPK activator 
SH-SY5Y: ↓syn110; ↓tau 
phosphorylation117, ↓A toxicity118 
Mice: ↓TH neuronal loss, ↑motor 
function (MPTP)119 
Trehalose 
Disaccharide. Abiotic stress 
protectant. Food-additive 
Glucose transporter inhibitor, 
↑AMP/AMPK activator 
PC12 : ↓syn (A30P/A53T) / ↓Htt 
(Q74)121;  
Cortical neurones: ↓tau 
(TauRDΔK280)122 
Mice: SOD1 (SOD1G93A)120 ; ↓Htt (R6/2- 
Htt150Q)124, ↓tauopathy (PS19-
MAPTP301S)125, ↓A (APP/PS1)123 
Lithium 
Mood stabiliser, anti-epileptic 
Evaluated in FTD and ALS 
↓Inositol monophosphate,  
AMPK activator? 
SK-N-SH: ↓Htt (HttQ74)126 
Mice: ↑survival (SOD1G93A)128; 
↓tau/filaments, ↑motor function, 
↑autophagy (JNPL3)127 
Methylene blue 
Dye. Treatment of 
methemoglobinemia. 
Development for AD/FTD 
(various formulations) 
AMPK activator, ↑beclin 1 
(also inhibitor of tau aggregation) 
HT-22: ↑AMPK, ↓cell death (serum 
deprivation)102;  
 Organoypic Hippocampal 
Slice/Neurones: ↓tau (JNPL3, 
MAPTP301L)101 
Mice: ↓tau (JNPL3)101 
Calcitriol 
 (Vitamin D 
metabolite) 
Treatment of Ca2++ deficiency. 
CaMKK2 potentiator upstream of 
AMPK 
_ 
Mice: ↓neurodegeneration 
(C57BL/6/MPTP)129 
 
mTOR1 Inhibition Macrolide. 
Immunosuppressant (organ 
transplants). Potential 
chemotherapy 
mTOR1 inhibitor 
PC12: ↓syn (MPTP)130, ↓Htt 
(HttQ74)131 
Cortical neurones: ↓FUS, 
↓stress granule (FUSR521C)132 
 
Drosophila: ↓Htt,↓neurodegeneration 
(HttQ74)133; 
 Mice: ↓Atau (3XTgAD)136, 
↓TDP43/p62 (FTLD-U/TDP43)134 and 
↓neuronal loss (MPTP)135 
Rapamycin 
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Temsirolimus Renal cell carcinoma mTOR1/2 inhibitor 
SH-SY5Y: ↓hyperphosphorylated tau  
(okadaic acid)137 
Mice : ↓tau (MAPTP301S)137, ↓-syn/ 
neuroprotection(MPTP)138, ↓Ataxin3 
(Ataxin3Q70)139;↓Htt/ ↑motor skills 
(R6/2)133 
Curcumin 
Tumeric extract. Food colour. 
Dietary supplement. 
Clinically evaluated in MCI 
Indirect mTOR1 repressor, 
p300 HAT inhibition causing Atg 
deactylation 
SH-SY5Y: ↓-syn aggregation (SynA53T) 
142,143;  
DA neurones: ↑neuroprotection 
(rotenone)141 
Mice: ↓A aggregation (Tg2576)146, 
↓tau dimers (hTau)145,  
↓-syn (GFP-Syn)144 
Fisetin 
Plant polyphenol.  
Anti-oxidant 
mTOR1-dependent activator of TFEB Cortical Neurones: ↓phospho-tau149 Mice: ↓A(APP/PS1)150 
Nilotinib 
Resistant chronic 
myelogenous leukemia. 
Clinically evaluated in PD 
C-Abl kinase inhibitor, 
upstream recruitment of mTOR1 
M17: ↓TDP43 (GFP-TDP43)154 
Mice: ↓syn, ↑motor function 
(SynA53T)153, ↓TDP43 (TDP43)154 
Sirtuin1 facilitation Vitaminin in food. Treatment 
of niacin deficiency. 
 Clinically evaluated in AD 
Nicotinamide adenine dinucleotide 
precursor/sirtuin1 promoter, 
Atg deacetylation 
Cortical Neurones: ↓Atoxicity  
(A25-35/1-42)158 
Mice: ↓Aand tau (3XTgAD)159 Nicotinamide 
 
Cilostazol 
Treatment of intermittent 
claudication. Platelet 
aggregation inhibitor. 
Phosphodiesterase 3 inhibitor, 
Upstream recruiter of Sirtuin-1 
N2a: ↓AAPPSWE);  
↑AMPK, ↓mTOR1, 
↑autophagosomes, ↑cathepsin B108 
Mice: ↓A↓phospho and  
acetylated-tau; ↑ cognition
(icv Aβ25-35)162,163   
Spermidine 
Natural polyamine. Potential 
promoter of longevity  
p300 HAT Inhibitor, Atg and Histone 
H3 deacetylator, ↑Beclin 1 
Cortical Neurones/PC12: ↑survival, 
↓toxicity (staurosporine)168 
Drosophila: ↑motor function (-syn) 170; 
C. elegans: ↓syn toxicity (UAS-GAL4-
-syn)170;  
↓TDP-43 (FTLD-U)169 
Autophagy activators: enhanced autophagosome formation 
Isorhynchophylline 
Plant alkaloid.  
Investigational compound 
↑Beclin 1 
DA Neurones/N2a: ↓syn (SynWT, 
SynA53T, SynA30P)175 - 
Auten-99 Investigational compound 
↑ PtdnIns3P activity (via Jumpy 
phosphatase inhibition) 
SH-SY5Y: ↑survival (H2O2)181 
Drosophila: ↓neurodegeneration, ↓p62 
(ParkinR275W)181 
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Enhancers of autophagosome fusion/transport 
Paclitaxel, 
 Epothilone D 
Chemotherapy of several 
cancers (Paclitaxel). 
Potential treatment for 
cancer (Epothilone) 
↑Cytoskeletal/microtubule  
transport of autophagosomes  
SH-SY5Y: ↓A-mediated cytoskeletal 
destabilization and ER stress (A25-
35)182 
Mice: ↓tau (PS19, TauP301S)183 
Enhancers of lysosomal digestion 
2-Hydroxypropyl-β-
cyclodextrin 
Investigational compound. 
(binds cholesterol) 
TFEB inducer; ↓endolysosomal 
cholesterol; ↓lysosomal pH; ↑ABCB1 
transporters (astrocytes) 
H4: ↓-syn aggregates(α-syn-GFP)195; 
N2a: ↓AAPPSWE)173 
Mice: ↓tau, ↓A plaques, ↑memory 
(Tg19959/CRND8)173 
Clioquinol 
Anti-fungal,  
anti-protozoal drug 
Zinc (and iron) chelator; 
 Increased lysosomal acidification. 
Fibroblasts: ↓syn(ATP13a2/PARK9 
knockdown)78 
Mice: ↓ATg2576197 
GZ/667161, 
GZ/SAR402671 
Investigational compounds, 
Clinically evaluated in PD 
Inhibitors of glucosylceramide 
synthesis, substrate reducers - 
Mice: ↓α-syn/ubiquitin/tau, 
↑memory(GBAD409V)199 
Miglustat 
Gaucher’s disease,  
Niemann-Pick Type C1 disease 
Inhibitor of glucosylceramide 
synthesis, 
substrate reducer 
Mesencephalic Neurones: ↓lipid 
accumulation in lysosomes (MPTP+ 
conditural-epoxide)75 
Mice: ↓substrate storage, ↑longevity 
(MPTP)75 
Ambroxol 
Secretolytic for respiratory 
diseases. Clinically evaluated 
in PD and Gaucher’s disease 
Chaperone: aids 
glucocerebrosidase transport to 
lysosome  
Dopaminergic Neurons: 
↓-syn (GBAN370S)200 
Drosophila: ↓ER stress (GBAN370S,L444P)201;  
Mice:↓-syn (SNCAXSNCAKOtm1Nbm)202 
NCGC607 
Salicyclic acid derivative. 
Investigational compound 
Chaperone: aids transport of 
glucocerebrosidase to lysosome - 
no catalytic inhibition 
Dopaminergic neurons from Gaucher’s 
patients: ↓glycolipids, ↓-syn 
(GBAN370S+/+, GBAN370S/c.84dupG)203 
- 
HEP14 Investigational compound 
Protein Kinase C-mediated TFEB 
activation and possibly ZKSCAN3 
inhibition 
- Mice: ↓A(APP/PS1)
151 
Facilitators of proteosomal (UPS-mediated) degradation 
Arimoclomol 
Niemann-Pick Type C1 
disease. 
Clinical evaluation for ALS 
Heat Shock Factor 1 stabilizer, 
Hsp70 chaperone production 
Motoneurones: ↑survival 
(staurosporine, H2O2)211 
Mice: ↓SOD1, ↓motor loss, ↑longevity 
(SOD1G93A)212 
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IU1/IU1-47 
Investigational compounds USP14 (deubiquitinase) inhibitors 
Cortical Neurones: ↓tau, Ub-proteins 
(Prostaglandin J2)215; ↑tau 
degradation and ↑ALN flux216 
 
- 
Geldanamycin 
 
Antibiotic. 
 Potential anti-tumorigenic 
 
Hsp90 inhibitor 
Hsp70 chaperone activity 
M17: tau (tau transfected)219; H4: α-
syn (α-syn-YFP complementation)220 
Drosophila:  α-syn (-synA306/504) 202 
Drosophila: insoluble (HttQ93)222;  
Mice: tau (JNPL3)219 
17-AAG 
Investigational compound. 
Potential anti-tumorigenic 
Hsp90 inhibitor (improved brain 
entry), Hsp70 chaperone activity 
H4: α-syn oligomers 
(α-syn-YFP complementation)220 
Mice:  A and synaptic 
toxicity/memory impairment 
(Tg2576)223,224, tau (JNP3L)224 
HSP990 Investigational compound 
Hsp90 inhibitor, HSF1 promoter, 
Hsp70 chaperone activity 
- 
Mice: Htt aggregates, motor 
performance (R6/2)225 
 
Rolipram 
Investigational compound. 
Potential use in auto-immune 
disorders 
Phosphodiesterase inhibitor, 
Protein Kinase A-mediated 
proteasome phosphorylation 
Cortical Neurones:  
A/α-syn synaptic damage 
(human brain extract)228 
Mice: tau, ubiquitin, improved 
cognition (rTg4510, JNPL3)229 
PD169316 Investigational compound 
p38 MAPK inhibitor, p38 MAPK 
proteasome phosphorylation 
 
α-syn (wild-type protein)233 - 
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Suppl	 Table	 1:	 Clinical	 trials	 undertaken	 in	 Neurodegenerative	 Disorders	 of	 Aging	 with	 drugs	 that	 experimentally	 modify	 the	 clearance	 of	
neurotoxic	proteins.	
	
The	 Table	 depicts	 those	 drugs	 affecting	 autophagic-lysosomal	 or	 ubiquitin-proteasomal	 clearance	 that	 have	 been,	 or	 are	 being,	 clinically	 evaluated	 for	 the	
treatment	of	neurodegenerative	disorders	of	aging.	The	clinical	trial	identifier	(with	hyperlink	to	https://clinicaltrials.gov/	information)	is	shown,	together	with	
the	 phase	 of	 testing,	 doses	 under	 study	 (oral)	 and	 primary	 measures/readouts	 used.	 The	 drugs	 shown	 were	 not	 necessarily	 developed	 as	 modulators	 of	
neurotoxic	protein	elimination	per	se	-	for	example,	TRx02371.	However,	based	on	experimental	data,	they	are	known	to	modulate	clearance.	In	addition	to	the	
drugs	 and	 studies	 indicated	 in	 the	 Table,	 an	 open	 label	 investigation	with	 rilmenidine	was	 recently	 undertaken	with	 a	 view	 of	 evaluating	 its	 efficacy	 in	 the	
treatment	of	Huntington’s	disease2.	For	mechanisms	of	drug	action	-	which	in	several	cases,	like	Lithium,	are	not	entirely	clear3	-	see	main	text	and	Table	2.	While	
resveratrol	did	not	reduce	brain	volume	 loss	 in	the	overall	 trial	 in	AD	and	MCI4,5	analysis	of	a	small	patient	subset	with	CSF	 levels	of	Aβ1-42	of	 less	than	600	
ng/ml,	 provided	 evidence	 for	 a	 favourable	 influence	 on	 the	 blood-brain	 barrier	 (blocked	 leakage	 due	 to	 decreased	 levels	 of	 Matrix	 Metalloprotease	 9),	 a	
reduction	in	immune-inflammatory	markers,	and	a	less	marked	decline	in	cognition	and	functional	performance5.	TRx0237	(LMTX	or	LMTM)	is	a	new	formulation	
of	methylene	 blue	 (methylthioninium	chloride)	 and	 a	 successor	 of	 Trx014	 (RemberTM).	 Further	 analysis	 of	 the	AD	 trial	 suggested	 that	 it	may	 have	 beneficial	
effects,	notably	on	brain	atrophy1,6	but	this	has	been	disputed	and	another	randomized	trial	would	be	needed	to	verify	this	post-hoc	interpretation.	Further,	the	
focus	 is	 now	 largely	 on	 the	 anti-aggregation	 properties	 of	 Trx0237,	 so	 it	 is	 unclear	 to	what	 extent	 induction	 of	 autophagy	 is	 involved	 in	 its	 clinical	 actions.	
Ironically,	 the	only	drug	to	have	received	FDA	authorization	 is	edaravone	yet,	as	discussed	 in	Suppl	Box	3,	edaravone	may	reduce	ALN	activity.	However,	 this	
remains	controversial	and	edaravone	has	other,	 therapeutically-useful	actions	 like	anti-oxidant	and	anti-aggregant	properties.	Abbreviations	not	 in	main	text:	
ADAS-Cog,	Alzheimer	Disease	Assessment	Scale;	ALSDRS-R,	ALS	Functional	Rating	Scale-Revised;	CGIC,	Clinician's	Global	Impression	of	Change;	FDDNP-PET	2-(1-
(6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl)-ethylidene)malononitrile	 -	 Positron	 Emission	 Tomography;	 GBA,	 β-Glucocerebrosidase;	 MCI,	 Mild	
cognitive	impairment;	MOCS,	Montreal	Cognitive	Score;	MRI,	Magnetic	Resonance	Imaging;	NPI,	Neuropsychiatric	inventory;	TBD,To	be	determined	and	UPDRS,	
Unified	Parkinson’s	Disease	Rating	Scale.	
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Drug	 Disorder	 Clinical	Trial	 Phase	 Dose	 Primary	Outcome	Measures		 Status	
Lithium	 FTD	 NCT02862210	 II	 150-600	mg/d	
Neuropsychiatric	Inventory	Scale;		
BDNF	serum	levels	and	changes	in	NPI	score	
Recruiting,	
	negative	in	ALS3	
Metformin	 Ageing	 NCT02432287	 IV	 1700	mg/d	 Gene	expression,	insulin	sensitivity	 Ongoing4	
Metformin	 MCI	 NCT00620191	 II	 1000	mg/2x/d	
Memory	recall,	ADAS-cog,	2-deoxy-2-fluoro-D-glucose	
positron	emission	tomography		
Completed,	minor	cognitive	
benefit;	other	markers	negative5	
Resveratrol	 AD,	MCI	 NCT00678431	 II	 Grape	juice	 ADAS-cog,	CGIC	 Completed,	unsuccessful	
Resveratrol	 AD	 NCT01504854	 II	
500-1000	
mg/2x/d	
Aβ−amyloid	1-42	levels,	brain	MRI;	
	Innate	immune/inflammatory	biomarkers;	
	Cognitive	and	functional	decline		
Completed,	no	change	in	brain	
volume;	positive	signals	in	
patient	subset	(see	legend)4,5	
Resveratrol	 HD	 NCT02336633	 III	 40	mg/2x/d	
Caudate	atrophy;	Unified	Huntington	Disease	Rating	
Scale;	Total	Functional	Capacity;	inorganic	
phosphate/phosphocreatine	levels	 Recruiting	
Nicotinamide	 AD	 NCT00580931	 I	 1500	mg/2x/d	 ADAS-cog	 Completed,	no	report	
TRx0237	
(LMTX/M)	 AD	 NCT0162639	 II	 100	mg/2x/d	
Safety	and	tolerability	with	Acetylcholinesterase	Inhibitor	
or	Memantine	co-administration	
Terminated1,6;	Post-hoc	analysis	
“positive”	(see	legend)	
TRx0237	
(LMTX/M)	 FTD	 NCT01626378	 III	 100	mg/2x/d	
Whole	brain	volume	(MRI);	Addenbrooke’s	Cognitive	
Exam;	Functional	Activities	questionnaire;	
Frontotemporal	Dementia	Rating	Scale;	Modified	CGIC	
Completed,		
unsuccessful7	
Curcumin	 MCI	 NCT01383161	 II	 465	mg/6x/d	
Cognitive	testing,	inflammation	markers;		
Aβ−amyloid	1-42	levels;	FDDNP-PET	 Ongoing	
Ambroxol	 PD	 NCT02941822	 II	
Escalating	doses	
60-420	mg/d	
Glucosylceramide	and	ambroxol	levels	in	CSF;	GCase	
activity;	Montreal	Cognitive	Assessment;	UPDRS		 Ongoing	
Ambroxol	 PD	 NCT02914366	 III	 525,1050	mg/d	
ADAS-cog;	CGIC;	MOCS;		
CSF	(α-syn;	tau;	Aβ);	MRI	(atrophy)	 Recruiting	
Arimoclomol	 ALS	 NCT00706147	 II/III	 200	mg/3x/d	 Rate	of	decline	on	ALSFRS-R,	safety	and	tolerability	
Well-tolerated;	low	adverse	
effects;	possible	increased	
survival;	slower	ALSFRS-R	
decline8 
Arimoclomol	 ALS	 NCT00244244	 II	 75-300mg/3x/d	
Safety,	tolerability,	pharmacokinetics;	rate	of	decline	on	
ALSFRS-R		
Well-tolerated,	low	adverse	
effects;	slower	ALSFRS-R	decline	
with	Arimoclomol9	
GZ/SAR402671	 PD		 NCT02906020	 II	
Escalating	doses	
TBD	
UPDRS,	Parkinson's	Disease	Cognitive	Rating	Scale;		
Hoehn	and	Yahr	score	 Recruiting	
Nilotinib	 PD	 NCT02281474	 I	 150,	300	mg/d	
Safety,	tolerability,	pharmacokinetics	and	biomarkers		
(homovanillic	acid		in	CSF)	
Completed,	potential	benefits	to	
confirm10	
Nilotinib	 PD	 NCT02954978	 II	 150,	300	mg/d	
Safety,	tolerability,	pharmacokinetics	and	biomarkers		
(homovanillic	acid	in	CSF)	 Recruiting	
Nilotinib	 AD	 NCT02947893	 II	 150,	300	mg/d	 Safety,	Biomarkers	and	Clinical	Outcomes	 Recruiting	
	
ALS	 NCT01492686	 III	 60	mg/d	 ALSFRS-R;	time	of	death;	health	changes	over	time	
Successful	(ALSFRS-R)11;	
FDA	approved	Edaravone	
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Supplementary Boxes  
 
Box S1: Lysosomal storage disorders: insights into the pathogenesis and treatment 
of neurodegenerative disorders of ageing (NDAs) 
The more than 50 recognised classes of lysosomal storage disease (LSDs)1, like 
Niemann-Pick disease type C, are genetically inherited disorders that arise from: 1), defects 
in the activity of lysosomal hydrolases that catabolise proteins and other autophagic cargo 
(primary storage disorders); 2), dysfunction of proteins involved in autophagic cargo 
sequestration and lysosomal delivery (secondary storage disorders)2 or 3) aberrant forms of 
proteins involved in cargo handling and exocytosis (tertiary storage disorders)3. Deficiencies 
in lysosomal hydrolases disrupt the sequential degradation of cellular substrates like 
proteins, sphingolipids and glycosaminoglycans2,4. Several LSDs are associated with  
neurodegeneration that commences in early childhood: for example, Tay-Sachs disease 
where β-hexosaminidase deficiency causes GM2-ganglioside accumulation. Further, since 
mutations are expressed body-wide, LSDs present with systemic complications like 
splenomegaly and cardiomyopathy1.  
Conceptually, NDAs might be considered, at least in part, as ‘storage’ disorders 
associated with the accumulation of incompletely-degraded proteins, such as α-synuclein in 
Parkinson disease (PD) and Aβ and tau protein in Alzheimer’s disease (AD)5. In NDAs, a 
reduction in lysosomal clearance of aggregated proteins and dysfunctional organelles is, 
then, associated with characteristic pathophysiological features (main text, Table 1). 
Although the lysosome is the final site of substrate degradation, and ‘classical’ LSDs 
are conventionally viewed as compartmentalized inborn errors of metabolism, the lysosome 
is part of a dynamic system integrating other cellular processes like endocytosis and 
autophagy (main text)1,6,7. Moreover, LSDs partly result from the sequestering of proteins 
and other substrates that would otherwise be recycled to serve as building blocks for 
meeting on-going cellular demands. A diversity of pathophysiologic events including 
decreased lysosomal acidity, neuroinflammation and dysregulation of calcium homeostasis 
are associated with LSDs and provide a mechanistic link to NDAs where similar pathological 
changes are seen1,8. As for the earlier age of symptom onset in LSDs vs NDAs, this is likely 
explained by the more radical impact of single gene defects that trigger from birth ON A loss 
of lysosomal (degradative) enzyme activity and rapid accumulation of substrates1,9. 
Conversely, in NDAs, the primary defect(s) are mainly extrinsic to the lysosomal 
compartment, the evolution of disease is slower and the rate of ‘substrate’ accumulation 
more protracted. Eventually, with the progressive accumulation of aggregated proteins, 
cellular storage surpasses a threshold (“inflection point”) that initiates a cascade of 
damaging events. 
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Parallels between LSD and NDAs are exemplified by Gaucher’s disease (GD) and 
PD. In GD, heterozygous mutations in GBA1, which encodes lysosomal β-
glucocerebrosidase, markedly increase the risk of PD. Conversely, a subset of sporadic PD 
patients present with disrupted function of β-glucocerebrosidase and lysosomal 
accumulation of its substrate, glucosylceramide10. Moreover, as recently reported11, around 
half of PD patients have at least one putatively deleterious mutation in genes associated with 
LSDs other than GBA11,12.  Lysosomal dysfunction is also of more general relevance to the 
pathogenesis of familial and idiopathic AD which, amongst other processes, can be linked to 
disruption of Presenilin-1, a protein driving lysosomal acidification10,11. Further comparisons 
of LSDs and NDAs should yield additional insights into their underlying and common causes, 
and also into potential therapies for restoring lysosomal function1.  
Approved disease-modifying treatments for LSDs include enzyme replacement 
therapies which deliver recombinant enzymes, such as β-glucocerebrosidase for GD 
disease, although this enzyme poorly enters the brain1,12. Substrate reduction therapy 
involves the inhibition of enzymes that normally synthesize the excess substrate: e.g., 
miglustat and eliglustat inhibit glucosylceramide synthase but, unfortunately, have limited 
access to the brain9. This type of therapy with better ability to penetrate the BBB (e.g., 
GZ/SAR402671), together with the use of chaperones to promote β-glucocerebrosidase 
transfer to lysosomes, is potentially useful for PD - see main text1. Another drug undergoing 
clinical testing is arimoclomol which is being evaluated in Niemann-Pick disease type C. It 
mimicked the ability of recombinant Heat Shock Factor 70 (a protein chaperone that 
promotes the binding of sphingolipid-degrading enzymes to their co-factors) to counter 
lysosomal defects in primary fibroblasts from this and other classes of LSD13. 
Important differences between NDAs and LSDs should not be neglected: not least, a 
dysfunction of clearance mechanisms other than the ALN is a core facet of the former 
diseases. Nonetheless, Research and Development programmes devoted to LSDs are 
proving instructive in the elucidation of pathological mechanisms underlying NDAs, and in 
the elaboration of novel strategies for their treatment1,14,15.	The first trial assessing the clinical 
benefit of GZ/SAR402671 has recently been launched in patients with PD bearing a GBA1 
mutation (NCT02906020) (Suppl Table 1). 
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Rev Drug Discov, 17, 133-150 doi:10.1038/nrd.2017.214 (2017). 
2 Schwake, M., Schroder, B. & Saftig, P. Lysosomal membrane proteins and their 
central role in physiology. Traffic 14, 739-748, doi:10.1111/tra.12056 (2013). 
3 Boland, B. & Platt, F. M. Bridging the age spectrum of neurodegenerative storage 
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Box S2: The Unfolded Protein Response: role in pathophysiology of 
neurodegenerative disorders of aging (NDA) and potential therapeutic targeting 
 In addition to clearance mechanisms discussed in the main text, maintenance of 
proteostasis requires effective folding and assembly of newly-synthesized proteins before 
they exit the endoplasmic reticulum (ER)1. When this process is insufficient and cells begin 
to accumulate misfolded and harmful proteins, the Unfolded Protein Response (UPR, see 
Glossary) is transiently triggered to let the cell recover. The UPR is integral to maintaining 
proteostasis and its modulation can affect autophagic processes1,2. 
 Transient UPR activation results in increased chaperone expression for protein re-
folding, and, via the kinase Protein Kinase RNA-like Endoplasmic Reticulum Kinase (PERK), 
a reduction in protein synthesis rates to reduce the ER burden.  However, chronic over-
activation of PERK signalling occurs in certain NDAs and has been implicated in 
neurotoxicity: hence, PERK down-regulation is a promising target for NDA treatment which 
can be considered as complimentary to the augmentation of clearance3. In mouse models, 
deregulated and excess PERK signalling causes a sustained and marked reduction in 
cerebral protein synthesis leading to synaptic dysfunction and neuronal death: this is 
reversible by genetic and pharmacological inhibition4,5.  Similar beneficial effects were 
observed using trazodone, an antidepressant that inhibits PERK signalling and is being 
repurposed for clinical trials in human NDAs3. Genetic or pharmacological modulation of the 
UPR also results in the activation of autophagy and has shown promising results in models 
of Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis6.  
 As mentioned above and discussed in the main text, disruption of proteostasis (and 
accumulation of neurotoxic proteins) is toxic, so cells initiate a series of adaptive responses. 
These include induction of clearance by the autophagic-lysosomal network (ALN) and the 
ubiquitin proteasome system (UPS), and reduced generation of proteins via activation of the 
UPR2. These adaptive responses (sometimes referred to as hormesis) can also be induced 
by a sub-toxic, low intensity stressor (“preconditioning”) which results in cellular protection 
against further toxic injury7,8.  Hormesis can be induced by many preconditioning stimuli like 
oxidative stress, ER stress and inflammatory stimuli8-11. It has been proposed that 
preconditioning of the UPR via mild ER stress may be neuroprotective. For example, in 
Drosophila models of apoptosis-induced retinal degeneration and human α−synuclein 
overexpression, ER-preconditioning elicited either genetically or with tunicamycin promoted 
neuroprotection by harnessing the ALN12. Similarly, in a 6-hydroxydopamine mouse model of 
Parkinson’s disease, preventive injection of tunicamycin reduced both dopaminergic neuron 
loss and locomotor dysfunction12. The interconnection between the UPR and clearance is 
also critical for neuroprotection in models of ischemia reperfusion2. Finally, modest activation 
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of X-box binding protein 1, a major transcription factor triggered by the UPR, leads to 
autophagic activation and neuroprotection in mouse models of ALS and HD13.  
Collectively, the above comments indicate that two UPR-articulated strategies may 
provide neuroprotection in NDAs: first, abrogation of an over-persistent and extreme UPR 
and, second, a mild and transient recruitment of the UPR as a means to engage ALN-driven 
clearance of neurotoxic proteins 
In addition to the cytosolic UPR discussed above, there is also a mitochondrial UPR 
which is activated to protect mitochondria from stressors like accumulation of unfolded 
proteins in their matrix14. These harmful, intra-mitochondrial proteins are digested by 
proteases and the resultant peptides exported to the cytosol: there, they trigger a cascade 
that restores proteostasis by inducing genes encoding, for example, mitochondrial 
chaperones. In addition, due to a decrease in the activity of mTOR, protein translation is 
reduced. Boosting the mitochondrial UPR and mitophagy with nicotinamide had beneficial 
effects on mitochondrial function in human cells expressing Aβ, as well as in mice models of 
AD where it helped to clear intracellular deposits of Aβ14,15. Finally, mitochondrial stress due 
to failure of protein import or sorting leads to the accumulation of proteins in the cytosol and 
to an overburdening of the UPS. Accordingly, agents that promote UPS activity may also be 
of therapeutic utility in NDAs associated with mitochondrial dysfunction16. 
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Box S3: Potentially detrimental effects of (excess) autophagic-lysosomal network 
(ALN) activity: relevance to amyotrophic lateral sclerosis (ALS) 
 
Excess activity of the ALN under specific conditions and its consequences  
While modest and time-locked ALN activation is protective, over-activation is 
potentially deleterious. Indeed, sustained and massive ALN activity in stroke or traumatic 
brain injury leads to tissue damage and even cell death (“autosis”) (Glossary) due to 
excessive catabolism and cellular stress1,2. While there is little or no evidence for excess 
ALN in most classes of NDA, this may potentially occur in ALS although, as outlined below, 
not all observations support this - still controversial - possibility. 
 
Evidence for a reduction in the activity of the ALN in ALS 
In post-mortem tissues of ALS patients, protein inclusions are seen in upper and 
lower motoneurons, as well as in neuronal and glial cells in the midbrain, prefrontal 
neocortex and striatum3-5. This argues for defective clearance of neurotoxic proteins, and 
one possible cause of compromised ALN activity is release by reactive astrocytes of 
Transforming Growth Factor β which interferes with initiation of autophagy by stimulating 
mTOR6. Further, a low handling capacity of the ALN - as reflected in the scarcity of beclin 1 
in the ventral horn of patients with sporadic or familial ALS - may be related to development 
of the disorder7. Indeed, by analogy to frontotemporal dementia8 and other classes of NDA 
(main text), defective autophagy has been proposed as a point of convergence point of 
harmful events in ALS, such as endoplasmic reticulum stress, mitochondrial dysfunction, 
anomalous processing of mRNA/miRNAs and oxidative stress9-11.  
Mutated Fused in Sarcoma (FUS), which accounts for about 5% of familial forms of 
ALS, inhibits the formation of autophagosome in neuronal cells as visualized in the 
accumulation of Light Chain-3 (LC-3) positive vesicles12. Negative regulation of autophagy 
has also been reported in cultured neurons transfected with mutated TAR DNA-binding 
protein-43 (TDP-43), while superoxide dismutase (SOD) 1 overexpression impairs fusion of 
autophagosome and lysosomes13. These results support ALN impairment, although 
conflicting with another paper which reported an upregulation of macroautophagy in cells 
transfected with TDP-43 or SOD114. Underpinning the pertinence of specific cell types. In 
symptomatic SOD1G93A (specific mutation) mice, expression of pro-autophagic markers is 
highly upregulated in muscle but not, or more moderately, in spinal cord15. These 
observations accord with the idea that muscle cells are more effective in clearing SOD1 by 
upregulating the ALN16. Nonetheless, muscles of SOD1G93A mice accumulate 
autophagosomes when compared to wild-type mice17, presumably due to insufficient ALN 
flux. 
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Evidence for an increase in the activity of the ALN in ALS 
Despite this evidence for reduced autophagic flux in ALS patients, this may not be 
true in all disease stages, for all ALS patients or, as intimated above, for all cell types. 
Moreover, ALN status may also depend on the precise genotype as highlighted by C9orf72. 
A hexanucleotide repeat expansion in the C9orf72 gene is a major cause of familial ALS. 
Although it is not clear whether C9orf72 mutations increase the propensity for ALS due to a 
loss and/or gain of function, carriers of expansion repeats present with reduced expression 
of C9orf7218. Their impact may, at least partially, be explained by a deregulation of 
autophagy19. Indeed, C9orf72 has been proposed as a negative regulator of 
mTOR/macroautophagy20 and its silencing enhanced autophagy flux in mice21. Thus, lower 
expression of C9orf72, or loss of function, could translate into higher autophagy flux for ALS 
patients. Indeed, there is clinical evidence for an up-regulation of the ALN in ALS. 
Expression and activity of lysosomal enzymes were higher in the spinal cord of ALS patients 
and animal models22,23. Underlining complexity, genetic removal of Atg7 in motoneurons 
inhibited macroautophagy in SOD1G93A mice and resulted in earlier disease onset yet longer 
survival24.  The loss of macroautophagy in motoneurons was also associated with reduced 
glial cell reactivity. Finally, SOD1 mutations caused overactivation of autophagy and cellular 
degeneration in SOD1 mutant mice25. This appeared to involve AMPK stimulation of Ulk1, 
and a reduction of AMPK activity conferred some modest neuroprotection26. Accordingly, 
treatment of cultured motoneurons from SOD1 mice with a AMPK stimulator exacerbated 
cytotoxicity suggesting that autophagic activity was already elevated (and deleterious) and 
that further stimulation might induce autosis27.  
 
Therapeutic control of excess ALN activity  
Collectively, the above observations are far from simple to reconcile (!), yet suggest a 
time, cause and cell-type dependent changes in specific components of the ALN. 
Mobilisation may well be beneficial for neuromuscular and neuronal integrity at disease 
onset, but “excess” autophagy in motoneurons may be toxic in late stages of the disease. As 
the main text focusses on efforts to promote ALN activity, the following comments evoke 
possibilities for tempering a putative hyperactivity under specific conditions in ALS. 
As mentioned above, agents that dampen an overactive ALN are mainly conceived 
for therapeutic use in stroke, cerebral ischemia and traumatic brain injury28,29 but data are 
emerging for ALS. Administration of n-butylidenephthalide, a natural compound which 
negatively regulates pro-autophagy proteins, extended survival of SOD1G93A mice30. 
Moreover, inhibition of β-glucocerebrosidase, a lysosomal enzyme participating in the 
degradation of glycosphingolipids, preserved neuromuscular junction and delayed 
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neurodegeneration in SOD1G86R mice31. Edaravone, a reactive oxygen species scavenger32, 
reduced cerebral autophagy in vivo after ischemia33 and also in macrophages34. This action 
is potentially linked to its utility for treating ALS35 and edaravone was approved for use in a 
subset of ALS patients36. It would be interesting to know their ALN status compared to other 
subjects who were not helped by treatment. Underscoring interest in edaravone, it improved 
cognition and diminished Aβ levels in a rat model of Alzheimer’s disease, and also displayed 
neuroprotective properties in a rotenone-induced model of PD37,38. However, its influence on 
Aβ appears to at least partly involve anti-aggregant properties, and it remains to be proven 
that ALN suppression is genuinely involved in the actions of edaravone38. Furthermore, not 
all data support the idea of promoting ALN activity in ALS. In this light, it is interesting to 
consider rilmenidine, a positive modulator of mTOR-independent macroautophagy (main 
text). In SOD1G93A mice, rilmenidine increased ALN flux in the spinal cord but ultimately 
exacerbated motoneuron degeneration and the accumulation of insoluble, misfolded SOD1 
protein14. 
 
Concluding comments  
In conclusion, ALS exemplifies the complexity of ALN deregulation in NDAs. Baseline 
flux may be inherently low at the onset of disease, related to old age and deficient actions of 
proteins encoded by genes like dynactin and progranulin (Table 1). Hence, the cell attempts 
to promote the ALN and this may initially be protective. However, later in the disease, under 
conditions of chronic cellular stress, energy imbalance and inflammation, “excess” ALN 
activity may become deleterious. Accordingly, there may be a phase-dependent need to 
therapeutically enhance or moderate ALN activity, potentially explaining contradictory 
findings in the literature. This remark also suggests that the duration and pattern as well as 
the time of drug administration would be critical. Finally, accentuating complexity, while this 
seems to hold for motoneurons and neuromuscular junctions, it remains to be more fully 
established how events unfold in spinal and cerebral neurons impacted in ALN. Much further 
research will be needed to clarify how to optimally harness the ALN for clearing neurotoxic 
proteins in ALS. 
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